,pmid,title,author,pubdate,keywords,prob,pmcid,table_info
0,11180036,Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.,Y Böttiger; J Säwe; C Brattström; J Tollemar; JT Burke; G Häss; JJ Zimmerman,2001,,0.9993782043457031,,
1,9013365,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants.,WJ Jusko; GM Ferron; SM Mis; BD Kahan; JJ Zimmerman,1996,,0.9992530941963196,,
2,23426978,A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.,S Urva; E Bouillaud; R Delaney; A Jappe; W Cheung,2013,,0.9990647435188293,,
3,9156373,Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration.,JJ Zimmerman; BD Kahan,1997,,0.9989423155784607,,
4,23735180,Comparative bioavailability and pharmacokinetics of sirolimus tablets in healthy Chinese volunteers.,MZ Huang; JC Chen; XJ Hu; J Liu; GL Wu; HL Zhou; MX Zhu; LH Wu; JZ Shen Tu,2013,,0.9989256262779236,,
5,19196220,Effects of oral posaconazole on the pharmacokinetics of sirolimus.,A Moton; L Ma; G Krishna; M Martinho; M Seiberling; J McLeod,2009,,0.9988633394241333,,
6,11034258,Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.,C Brattström; J Säwe; B Jansson; A Lönnebo; J Nordin; JJ Zimmerman; JT Burke; CG Groth,2000,,0.9988419413566589,,
7,30256541,"Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.",BE Houk; CW Alvey; R Visswanathan; L Kirkovsky; KT Matschke; E Kimoto; T Ryder; RS Obach; C Durairaj,2019,PF-05212384; PI3K; gedatolisib; metabolism; pharmacokinetics,0.9986546039581299,,
8,19606088,Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics.,F Braun; H Schöcklmann; E Ziegler; U Kunzendorf; VW Armstrong; L Renders,2009,,0.9986442923545837,,
9,16750634,Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients.,N Baldan; P Rigotti; L Furian; G Margani; B Ekser; L Frison; S De Martin; P Palatini,2006,,0.9985847473144531,,
10,22921184,Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.,D Mahadevan; EG Chiorean; WB Harris; DD Von Hoff; A Stejskal-Barnett; W Qi; SP Anthony; AE Younger; DM Rensvold; F Cordova; CF Shelton; MD Becker; JR Garlich; DL Durden; RK Ramanathan,2012,,0.9985275268554688,PMC3826796,
11,26714164,Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.,G Bernadou; M Campone; JL Merlin; V Gouilleux-Gruart; T Bachelot; F Lokiec; K Rezai; M Arnedos; V Diéras; M Jimenez; G Paintaud; D Ternant,2016,breast cancer; pharmacokinetics; population PK modelling; trastuzumab,0.9985249638557434,PMC4834606,
12,17532692,"Pharmacokinetics and Safety of ABT-578, a Sirolimus (Rapamycin) Analogue, after Single Intravenous Bolus Injection in Healthy Male Volunteers.",R Palaparthy; R Pradhan; J Chan; Q Wang; Q Ji; R Achari; T Chira; LB Schwartz; R O'dea,2005,,0.9985206723213196,,
13,27128614,Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients.,HF Wang; F Qiu; X Wu; J Fang; P Crownover; J Korth-Bradley; S Schulman,2014,Chinese; pharmacogenomics; pharmacokinetics; renal transplant; sirolimus,0.9984853863716125,,
14,20305057,"Randomized, double-blind, placebo-controlled, single intravenous dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of the novel coronary smooth muscle cell proliferation inhibitor Biolimus A9 in healthy individuals.",W Steudel; C Dingmann; YL Zhang; J Bendrick-Peart; C Clavijo; J Shulze; R Betts; U Christians,2011,,0.9984692931175232,,
15,12752317,Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.,JM Kovarik; B Kaplan; HT Silva; BD Kahan; J Dantal; L McMahon; S Berthier; CH Hsu; C Rordorf,2003,,0.9984678626060486,,
16,24496004,Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.,PA Jänne; RB Cohen; AD Laird; S Macé; JA Engelman; R Ruiz-Soto; K Rockich; J Xu; GI Shapiro; P Martinez; E Felip,2014,,0.9984305500984192,,
17,23266742,Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.,RK Goyal; K Han; DA Wall; MA Pulsipher; N Bunin; SA Grupp; SR Mada; R Venkataramanan,2013,,0.9984093308448792,PMC4231793,
18,31089971,Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers.,O Basa-Dénes; R Angi; B Kárpáti; T Jordán; Z Ötvös; N Erdősi; A Ujhelyi; B Ordasi; L Molnár; J McDermott; C Roe; L McKenzie; T Solymosi; G Heltovics; H Glavinas,2019,,0.9984059929847717,,
19,23052408,The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.,MA Tortorici; V Parks; K Matschke; J Korth-Bradley; A Patat,2013,,0.9983808994293213,,
20,27798513,Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients.,E David-Neto; F Agena; F Ramos; AHK Triboni; P Romano; P de Almeida Rezende Ebner; V Coelho; NZ Galante; FBC Lemos,2017,,0.9983149766921997,,
21,19808140,Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.,G Lunardi; A Armirotti; M Nicodemo; L Cavallini; G Damonte; MO Vannozzi; M Venturini,2009,,0.9982442855834961,,
22,17175302,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.,JM Kovarik; JJ Curtis; DE Hricik; MD Pescovitz; V Scantlebury; A Vasquez,2006,,0.9982084035873413,,
23,21809026,Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.,MJ Deenen; HJ Klümpen; DJ Richel; RW Sparidans; MJ Weterman; JH Beijnen; JH Schellens; JW Wilmink,2012,,0.9981562495231628,PMC3388253,PK - Table 4 | Study Population - Table 1
24,22549011,"Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.",HC Shin; H Cho; TC Lai; KR Kozak; JM Kolesar; GS Kwon,2012,,0.997857391834259,PMC3422612,
25,18332470,Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.,A O'Donnell; S Faivre; HA Burris; D Rea; V Papadimitrakopoulou; N Shand; HA Lane; K Hazell; U Zoellner; JM Kovarik; C Brock; S Jones; E Raymond; I Judson,2008,,0.997713565826416,,
26,1485369,Pharmacokinetics of rapamycin: single-dose studies in the rabbit.,N Honcharik; J Fryer; R Yatscoff,1992,,0.9976937174797058,,
27,16342216,Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.,GW Vetrovec; D Rizik; C Williard; D Snead; V Piotrovski; G Kopia,2006,,0.9976869821548462,,
28,16979990,Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.,CH Wang; NK Chou; FL Wu; WJ Ko; CI Tsao; NH Chi; RB Hsu; SS Wang,2006,,0.9975917339324951,,
29,27273343,"Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.",AH Groll; A Desai; D Han; C Howieson; K Kato; S Akhtar; D Kowalski; C Lademacher; W Lewis; H Pearlman; D Mandarino; T Yamazaki; R Townsend,2017,cyclosporine; isavuconazole; mycophenolate mofetil; prednisolone; sirolimus; tacrolimus,0.9975887537002563,PMC5298005,"PK - Table 2, Table 3, Table 4 | Study Population - Table 1"
30,14517200,Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers.,JJ Zimmerman; D Harper; J Getsy; WJ Jusko,2003,,0.9975131750106812,,
31,11831546,Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.,JM Kovarik; S Hartmann; M Hubert; S Berthier; W Schneider; B Rosenkranz; C Rordorf,2002,,0.997469425201416,,
32,22872575,Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.,EE Cohen; K Wu; C Hartford; M Kocherginsky; KN Eaton; Y Zha; A Nallari; ML Maitland; K Fox-Kay; K Moshier; L House; J Ramirez; SD Undevia; GF Fleming; TF Gajewski; MJ Ratain,2012,,0.9974609613418579,PMC4410974,
33,15084173,Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients.,M Schubert; R Venkataramanan; DW Holt; LM Shaw; W McGhee; J Reyes; S Webber; R Sindhi,2004,,0.9973794221878052,,
34,26709938,Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs.,JC Larson; SD Allstadt; TM Fan; C Khanna; PJ Lunghofer; RJ Hansen; DL Gustafson; AM Legendre; GD Galyon; AK LeBlanc; T Martin-Jimenez,2016,,0.997338593006134,PMC5642271,
35,20564143,"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.",SS Ramalingam; RD Harvey; N Saba; TK Owonikoko; J Kauh; DM Shin; SY Sun; S Strychor; M Tighiouart; MJ Egorin; H Fu; FR Khuri,2010,,0.9973374009132385,PMC2940062,
36,27117038,Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients.,M Wang; BL Duan; YJ Yuan; X Su; H Zheng; FS Wang; H Sun,2016,,0.9972829818725586,,
37,9892474,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits.,GM Ferron; WJ Jusko,1998,,0.9971814155578613,,
38,15848558,Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.,W El Haggan; M Ficheux; D Debruyne; N Rognant; T Lobbedez; C Allard; A Coquerel; JP Ryckelynck; B Hurault de Ligny,2005,,0.9971374273300171,,
39,21232120,Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors.,B Xu; Y Wu; L Shen; D Ye; A Jappe; A Cherfi; H Wang; R Yuan,2011,,0.9971248507499695,PMC3032760,
40,32005746,"A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.",TK Owonikoko; RD Harvey; B Carthon; Z Chen; C Lewis; H Collins; C Zhang; DH Lawson; OB Alese; MA Bilen; GL Sica; CE Steuer; WL Shaib; C Wu; WB Harris; M Akce; RR Kudchagkar; BF El-Rayes; S Lonial; SS Ramalingam; FR Khuri,2020,,0.9971064925193787,,
41,16236048,Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients.,Y Böttiger; C Brattström; L Bäckman; K Claesson; JT Burke,2005,,0.996866762638092,PMC1884939,
42,17020981,A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.,M Hidalgo; JC Buckner; C Erlichman; MS Pollack; JP Boni; G Dukart; B Marshall; L Speicher; L Moore; EK Rowinsky,2006,,0.9968202114105225,,
43,30758651,"Phase I study of orally administered 14Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies.",A MacDonald; G Scarfe; D Magirr; T Sarvotham; J Charlton; W Brugger; E Dean,2019,ADME; AZD2014; Metabolism; Phase I; Solid malignancies; Vistusertib,0.9967492818832397,,
44,9129559,Population pharmacokinetics of sirolimus in kidney transplant patients.,GM Ferron; EV Mishina; JJ Zimmerman; WJ Jusko,1997,,0.9967069029808044,,
45,11837553,Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.,JM Kovarik; S Hartmann; J Figueiredo; C Rordorf; G Golor; A Lison; K Budde; HH Neumayer,2002,,0.9967051148414612,,
46,32132091,Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947.,X Liu; X Liang; J LeCouter; S Ubhayakar; J Chen; J Cheng; T Lee; J Lubach; J Nonomiya; S Shahidi-Latham; C Quiason; E Solon; M Wright; CECA Hop; TP Heffron,2020,,0.9966892600059509,,
47,15049795,"Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.",A Tejani; S Alexander; R Ettenger; G Lerner; J Zimmerman; E Kohaut; DM Briscoe,2004,,0.9966763257980347,,
48,23519998,Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.,RK Kelley; HS Nimeiri; PN Munster; MT Vergo; Y Huang; CM Li; J Hwang; MF Mulcahy; BM Yeh; P Kuhn; MS Luttgen; JA Grabowsky; L Stucky-Marshall; WM Korn; AH Ko; EK Bergsland; AB Benson; AP Venook,2013,hepatocellular carcinoma; mTOR; pharmacokinetics; sorafenib; temsirolimus,0.9966553449630737,PMC3690907,
49,30627287,Pharmacokinetic Study of Sirolimus-Eluting BioResorbable Vascular Scaffold System for Treatment of De Novo Native Coronary Lesions: A Sub-Study of MeRes-1 Trial.,P Chandra; AU Mahajan; VD Bulani; AS Thakkar,2018,Bioresorbable vascular scaffold; Pharmacokinetics; Sirolimus,0.9966108202934265,PMC6306117,
50,15899725,Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.,FL Wu; MK Tsai; RR Chen; SW Sun; JD Huang; RH Hu; KH Chen; PH Lee,2005,,0.9965751767158508,,
51,12796032,"Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.",CJ Punt; J Boni; U Bruntsch; M Peters; C Thielert,2003,,0.9965196847915649,,
52,9465841,The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.,B Kaplan; HU Meier-Kriesche; KL Napoli; BD Kahan,1998,,0.9964979887008667,,
53,18721002,"Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.",D Padhi; M Salfi; M Emery,2008,,0.9962789416313171,,
54,11069439,Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.,GI Kirchner; M Winkler; L Mueller; C Vidal; W Jacobsen; A Franzke; S Wagner; S Blick; MP Manns; KF Sewing,2000,,0.9962512850761414,PMC2014408,
55,27169792,Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer.,D de Wit; TC Schneider; DJ Moes; CF Roozen; J den Hartigh; H Gelderblom; HJ Guchelaar; JJ van der Hoeven; TP Links; E Kapiteijn; NP van Erp,2016,Everolimus; Exposure–toxicity; Individualized dosing; Pharmacogenetics; Population pharmacokinetics,0.9961779117584229,PMC4921118,PK - Table 2 | Study Population - Table 1
56,25300944,"Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma.",KP Papadopoulos; C Egile; R Ruiz-Soto; J Jiang; W Shi; F Bentzien; D Rasco; P Abrisqueta; JM Vose; J Tabernero,2015,PI3K; lymphoma; mTOR; pharmacodynamics; pharmacokinetics; signaling therapies,0.9961607456207275,,
57,29660598,"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).",A Wicki; N Brown; A Xyrafas; V Bize; H Hawle; S Berardi; N Cmiljanović; V Cmiljanović; M Stumm; S Dimitrijević; R Herrmann; V Prêtre; R Ritschard; A Tzankov; V Hess; A Childs; C Hierro; J Rodon; D Hess; M Joerger; R von Moos; C Sessa; R Kristeleit,2018,PI3K; PQR309; Phase 1; Solid tumours; mTOR,0.9961434006690979,,
58,10579146,The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin).,JJ Zimmerman; GM Ferron; HK Lim; V Parker,1999,,0.9961351156234741,,
59,34295160,Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles.,HJ Shin; MJ Jo; IS Jin; CW Park; JS Kim; DH Shin,2021,bioavailability; biodistribution; combination therapy; cytotoxicity; drug interaction,0.996109664440155,PMC8291852,
60,18474873,"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.",MQ Lacy; M Alsina; R Fonseca; ML Paccagnella; CL Melvin; D Yin; A Sharma; M Enriquez Sarano; M Pollak; S Jagannath; P Richardson; A Gualberto,2008,,0.996013879776001,,
61,21427078,Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.,N Lloberas; J Torras; JM Cruzado; F Andreu; F Oppenheimer; J Sánchez-Plumed; MÁ Gentil; M Brunet; H Ekberg; JM Grinyó; ,2011,,0.9958168864250183,,
62,17096757,Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.,AD Schachter; MR Benfield; RJ Wyatt; PC Grimm; RS Fennell; JT Herrin; DS Lirenman; RA McDonald; R Munoz-Arizpe; WE Harmon,2006,,0.995793342590332,PMC1636453,
63,30956975,The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats.,F Zhang; L Sun; J Zhai; T Xia; W Jiang; M Li; S Gao; X Tao; W Chen; Y Chai,2019,,0.9957689046859741,PMC6431440,"PK - Table 1, Table 2 | Study Population - None"
64,27121219,Comparative Sirolimus Pharmacokinetics After Single-Dose Administration of Two Prototype 0.5-mg Tablets in Healthy Volunteers.,JM Korth-Bradley; I Bhattacharya; K Matschke; AM Diehl; C Longfellow; I Gourley,2012,Rapamune; bioequivalence; pharmacokinetics; sirolimus,0.9956721067428589,,
65,19790241,Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.,A Yokomasu; I Yano; E Sato; S Masuda; T Katsura; K Inui,2009,,0.9956120252609253,,
66,25017487,The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.,L Rostaing; MH Christiaans; JM Kovarik; J Pascual,2014,,0.9955753087997437,,
67,15951468,Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.,K Budde; G Lehne; M Winkler; L Renders; A Lison; L Fritsche; JP Soulillou; P Fauchald; HH Neumayer; J Dantal; ,2005,,0.9955347776412964,,
68,16187976,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.,JM Kovarik; D Beyer; MN Bizot; Q Jiang; MJ Allison; RL Schmouder,2005,,0.9954987168312073,PMC1884822,
69,16623021,Pharmacokinetics of sirolimus in Thai healthy volunteers.,A Leelahavanichkul; N Areepium; S Vadcharavivad; K Praditpornsilpa; Y Avihingsanon; T Karnjanabuchmd; S Eiam-Ong; K Tungsanga,2005,,0.9952771663665771,,
70,11719728,Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.,JM Kovarik; HD Sabia; J Figueiredo; H Zimmermann; C Reynolds; SC Dilzer; K Lasseter; C Rordorf,2001,,0.9952676296234131,,
71,11180038,"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.",JM Kovarik; BD Kahan; B Kaplan; M Lorber; M Winkler; M Rouilly; C Gerbeau; N Cambon; R Boger; C Rordorf; ,2001,,0.9952157735824585,,
72,18039566,The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.,A Awada; F Cardoso; C Fontaine; L Dirix; J De Grève; C Sotiriou; J Steinseifer; C Wouters; C Tanaka; U Zoellner; P Tang; M Piccart,2008,,0.9951310157775879,,
73,29556934,A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.,I Robertsen; J Debord; A Åsberg; P Marquet; JB Woillard,2018,,0.9949938654899597,,
74,28032910,Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial.,ME Pavel; C Becerra; K Grosch; W Cheung; J Hasskarl; JC Yao,2017,,0.9949479103088379,,
75,26990259,Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.,T Niioka; H Kagaya; M Saito; T Inoue; K Numakura; R Yamamoto; Y Akamine; T Habuchi; S Satoh; M Miura,2016,CYP3A5 genotype; everolimus; pharmacokinetic interaction; renal transplantation; tacrolimus,0.9949207901954651,,
76,19122342,Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats.,A Yokomasu; I Yano; E Sato; S Masuda; T Katsura; K Inui,2008,,0.9947463870048523,,
77,12829916,Everolimus in pediatric de nova renal transplant patients.,PF Hoyer; R Ettenger; JM Kovarik; NJ Webb; J Lemire; M Mentser; J Mahan; C Loirat; P Niaudet; R VanDamme-Lombaerts; G Offner; S Wehr; V Moeller; H Mayer; ,2003,,0.9947447776794434,,
78,12022896,Effect of rifampin on apparent clearance of everolimus.,JM Kovarik; S Hartmann; J Figueiredo; M Rouilly; A Port; C Rordorf,2002,,0.9942252039909363,,
79,25653564,"Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers.",K Thudium; J Gallo; E Bouillaud; C Sachs; S Eddy; W Cheung,2015,absorption kinetics; healthy volunteers,0.9941893815994263,PMC4310326,"PK - Table 2, Table 3 | Study Population - Table 1"
80,22143911,Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts.,J Reichen; F Stickel; I Bhattacharya; K Matschke; E Maller; J Korth-Bradley,2012,,0.9941248297691345,,
81,19357111,"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.",JM Grinyó; H Ekberg; RD Mamelok; F Oppenheimer; J Sánchez-Plumed; MA Gentil; D Hernandez; DR Kuypers; M Brunet,2009,,0.9938046932220459,,
82,24057042,Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.,SM Gadgeel; DL Lew; TW Synold; P LoRusso; V Chung; SD Christensen; DC Smith; L Kingsbury; A Hoering; R Kurzrock,2013,,0.9937186241149902,PMC4072025,
83,19267777,"Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.",SI Park; CR Felipe; PG Pinheiro-Machado; R Garcia; FB Fernandes; DE Casarini; H Tedesco-Silva; JO Medina-Pestana,2009,,0.993425726890564,,
84,22143378,"Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.",Y Seki; N Yamamoto; Y Tamura; Y Goto; T Shibata; M Tanioka; H Asahina; H Nokihara; Y Yamada; T Shimamoto; K Noguchi; T Tamura,2012,,0.9933424592018127,PMC3313018,PK - Table 4 | Study Population - Table 1
85,18094423,Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.,JG Kuhn; SM Chang; PY Wen; TF Cloughesy; H Greenberg; D Schiff; C Conrad; KL Fink; HI Robins; M Mehta; L DeAngelis; J Raizer; K Hess; KR Lamborn; J Dancey; MD Prados; ,2007,,0.9930475354194641,PMC4918812,
86,15251382,Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment.,ED Moloney; U O'Mahony; M Kirwan; J McCarthy; J Hurley; AE Wood; JJ Egan,2004,,0.9930253028869629,,
87,20972652,Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.,K Tobinai; M Ogura; D Maruyama; T Uchida; N Uike; I Choi; K Ishizawa; K Itoh; K Ando; M Taniwaki; N Shimada; K Kobayashi,2010,,0.9929975271224976,,
88,27128230,The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers.,MA Tortorici; K Matschke; JM Korth-Bradley; C DiLea; KC Lasseter,2014,drug interaction; healthy volunteers; rifampin; sirolimus,0.9929505586624146,,
89,23453404,"Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.",J Peveling-Oberhag; S Zeuzem; WP Yong; T Kunz; T Paquet; E Bouillaud; S Urva; O Anak; D Sellami; Z Kobalava,2013,,0.9928760528564453,,
90,27713169,A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.,AD Pearson; SM Federico; I Aerts; DR Hargrave; SG DuBois; R Iannone; RD Geschwindt; R Wang; FG Haluska; TM Trippett; B Geoerger,2016,mTOR; pharmacokinetics; phase I-III trials_pediatric cancers; phase I-III trials_sarcoma/soft-tissue malignancies; ridaforolimus,0.9925743341445923,PMC5356695,
91,23666574,Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.,JR Scott; JD Courter; SN Saldaña; BC Widemann; M Fisher; B Weiss; J Perentesis; AA Vinks,2013,,0.9925585985183716,PMC3660960,
92,31452734,Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study.,D Wang; X Chen; Z Li,2019,kaposiform hemangioendothelioma; pediatric; population pharmacokinetics; real-world study; sirolimus,0.9925238490104675,PMC6676569,
93,22669570,The minimal impact of food on the pharmacokinetics of ridaforolimus.,M Stroh; X Li; S Marsilio; D Panebianco; A Johnson-Levonas; A Juan; K Orford; N Agrawal; M Trucksis; JA Wagner; G Murphy; M Iwamoto,2012,,0.9924766421318054,,
94,28282611,Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.,C Massard; KN Chi; D Castellano; J de Bono; G Gravis; L Dirix; JP Machiels; A Mita; B Mellado; S Turri; J Maier; D Csonka; A Chakravartty; K Fizazi,2017,Abiraterone acetate (AA); Buparlisib (BKM120); Castration-resistant prostate cancer (CRPC); Dactolisib (BEZ235),0.9923375248908997,,
95,16027401,A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.,CS Karyekar; RS Pradhan; T Freeney; Q Ji; T Edeki; W Chiu; WM Awni; C Locke; LB Schwartz; RG Granneman; R O'Dea,2005,,0.9922458529472351,,
96,24935294,Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients.,K Uchida; K Hoshinaga; Y Watarai; N Goto; M Kusaka; H Sasaki; M Hirano; ,2014,,0.9920467138290405,,
97,17913896,Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.,J Boni; C Leister; J Burns; M Cincotta; B Hug; L Moore,2007,,0.9919072389602661,,
98,17192769,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients.,L Renders; M Frisman; M Ufer; I Mosyagin; S Haenisch; U Ott; A Caliebe; M Dechant; F Braun; U Kunzendorf; I Cascorbi,2007,,0.9918855428695679,,
99,12616666,"Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.",JM Kovarik; A Noe; S Berthier; L McMahon; WK Langholff; AS Marion; PF Hoyer; R Ettenger; C Rordorf,2003,,0.991759717464447,,
100,27299325,A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients.,NP van Erp; CM van Herpen; D de Wit; A Willemsen; DM Burger; AD Huitema; E Kapiteijn; R Ter Heine,2016,,0.9916764497756958,PMC5069307,PK - None | Study Population - Table 1
101,24655978,Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.,A Wanitchanont; P Somparn; S Vadcharavivad; W Chancharoenthana; N Townamchai; K Praditpornsilpa; Y Avihingsanon,2014,,0.9916573762893677,,
102,19426700,Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.,C Chu; C Abbara; MS Noël-Hudson; L Thomas-Bourgneuf; P Gonin; R Farinotti; L Bonhomme-Faivre,2009,,0.9915834069252014,,
103,24659021,No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.,N Chen; D Weiss; J Reyes; L Liu; C Kasserra; X Wang; S Zhou; G Kumar; L Weiss; M Palmisano,2014,,0.9915081262588501,PMC4000408,"PK - Table 1, Table 2 | Study Population - None"
104,8878394,Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats.,SM Stepkowski; KL Napoli; ME Wang; X Qu; TC Chou; BD Kahan,1996,,0.9914678335189819,,
105,17555465,"Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.",MD Pescovitz; F Vincenti; M Hart; L Melton; J Whelchel; S Mulgaonkar; D McKay; M Leung; E Calleja; MR Bouw,2007,,0.9913698434829712,PMC2198786,
106,27661398,Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma.,A Tanaka; I Yano; K Shinsako; E Sato; M Fukudo; S Masuda; T Yamasaki; T Kamba; O Ogawa; K Matsubara,2016,,0.9912247061729431,,
107,11583941,Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.,RB Ettenger; EM Grimm,2001,,0.9912245869636536,,
108,20430774,A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.,Y Fujisaka; Y Yamada; N Yamamoto; A Horiike; T Tamura,2010,,0.9909729957580566,,
109,21984222,Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.,DA Reardon; T Cloughesy; J Rich; WK Alfred Yung; L Yung; C DiLea; J Huang; M Dugan; W Mietlowski; A Maes; C Conrad,2012,,0.9906959533691406,,
110,23726267,Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.,MN Fishman; S Srinivas; RJ Hauke; RJ Amato; B Esteves; MM Cotreau; AL Strahs; WJ Slichenmyer; P Bhargava; FF Kabbinavar,2013,Dose escalation; Maximum tolerated dose; Pharmacokinetics; Renal cell carcinoma; Temsirolimus; Tivozanib,0.9906734824180603,PMC4666006,
111,26177599,"A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.",JC Bendell; RK Kelley; KC Shih; JA Grabowsky; E Bergsland; S Jones; T Martin; JR Infante; PS Mischel; T Matsutani; S Xu; L Wong; Y Liu; X Wu; DS Mortensen; R Chopra; K Hege; PN Munster,2015,AKT; mTOR; mTORC1/mTORC2; rapalogs,0.9906467199325562,PMC4832308,
112,25344362,A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.,AW Tolcher; JC Bendell; KP Papadopoulos; HA Burris; A Patnaik; SF Jones; D Rasco; DS Cox; M Durante; KM Bellew; J Park; NT Le; JR Infante,2015,MEK inhibitor; advanced solid tumors; everolimus; mTOR inhibitor; pancreatic cancer; trametinib,0.9905592203140259,,
113,19127256,Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.,M Campone; V Levy; E Bourbouloux; D Berton Rigaud; D Bootle; C Dutreix; U Zoellner; N Shand; F Calvo; E Raymond,2009,,0.9904161691665649,PMC2634724,PK - Table 4 | Study Population - Table 1
114,32720540,The first study in pediatric: Population pharmacokinetics of sirolimus and its application in Chinese children with immune cytopenia.,X Cheng; Y Zhao; H Gu; L Zhao; Y Zang; X Wang; R Wu,2020,immune cytopenia; immunosuppressant; pediatrics; population pharmacokinetics; sirolimus,0.9903447031974792,PMC7388097,PK - Table 3 | Study Population - Table 1
115,21299636,Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.,S Stracke; M Shipkova; J Mayer; F Keller; A Zarghom; L Yang; D Henne-Bruns; E Wieland,2012,,0.9902796149253845,,
116,23018254,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.,D Żochowska; J Wyzgał; L Pączek,2012,,0.990251898765564,,
117,20963405,The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK Study.,MC Ostojic; Z Perisic; D Sagic; R Jung; YL Zhang; J Bendrick-Peart; R Betts; U Christians; ,2011,,0.9900853633880615,,
118,28004284,A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.,CE Kyriakopoulos; AM Braden; JM Kolesar; JC Eickhoff; HH Bailey; J Heideman; G Liu; KB Wisinski,2017,C-met; PI3K/AKT/mTOR; Phase I; Temsirolimus; Tivantinib,0.9898077845573425,PMC5809175,
119,15498365,Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model.,MY Yu; RL Gao; J Jiang; SJ Cheng; JQ Yuan; CN Wang; JG Zheng; L Meng; ZJ Zi,2004,,0.9896962642669678,,
120,22051872,Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature.,J Lammer; D Scheinert; F Vermassen; R Koppensteiner; KA Hausegger; H Schroë; RM Menon; LB Schwartz,2012,,0.9896824955940247,,
121,19660003,Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.,Z Jiao; XJ Shi; ZD Li; MK Zhong,2009,,0.9895346760749817,PMC2732940,
122,23829943,A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors.,L Liu; W Zhang; W Li; F Lv; Z Xia; S Zhang; W Liu; AS Zandvliet; S Waajen; LX Zhang; L Yan; J Li,2013,,0.9894546270370483,PMC3716995,PK - Table 2 | Study Population - Table 1
123,8281627,"Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse.",JG Supko; L Malspeis,1994,,0.9894473552703857,,
124,10533695,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.,GM Ferron; NA Pyszczynski; WJ Jusko,1999,,0.9893220663070679,,
125,26274696,Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.,CR Felipe; NI Oliveira; PG Hannun; MI de Paula; H Tedesco-Silva; JO Medina-Pestana,2016,,0.9892023205757141,,
126,29648533,Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: Case report.,K Nakagita; K Wada; Y Terada; S Matsuda; N Terakawa; A Oita; M Takada,2018,,0.988980770111084,,
127,20137762,Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration.,JM Kovarik; M Bartlett; C Rordorf; MC Antunes; S Winter; P Marbach; S van Marle,2010,,0.9889109134674072,,
128,32993794,A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.,F Lang; L Wunderle; S Badura; E Schleyer; M Brüggemann; H Serve; S Schnittger; N Gökbuget; H Pfeifer; S Wagner; K Ashelford; G Bug; OG Ottmann,2020,BEZ235; PI3K/mTor inhibition; Phase I clinical trial; Refractory ALL; Refractory AML,0.9882813096046448,PMC7523358,
129,28676933,"Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.",LC Mbatchi; M Gassiot; P Pourquier; A Goberna; H Mahammedi; L Mourey; F Joly; S Lumbroso; A Evrard; N Houede,2017,ABCB1; CYP3A5; NR1I2; Pharmacogenetics; Pharmacokinetics; Temsirolimus,0.9881460666656494,,
130,28700521,Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.,J Zhang; Y Dai; Z Liu; M Zhang; C Li; D Chen; H Song,2017,,0.9879652261734009,,
131,12883227,Long-term pharmacokinetic study of the novel combination of tacrolimus and sirolimus in de novo renal allograft recipients.,DR Kuypers; K Claes; P Evenepoel; B Maes; Y Vanrenterghem,2003,,0.9877774119377136,,
132,17393166,Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.,JA Yáñez; ML Forrest; Y Ohgami; GS Kwon; NM Davies,2008,,0.9876688122749329,PMC2259393,
133,17947729,Phase I study of everolimus in pediatric patients with refractory solid tumors.,M Fouladi; F Laningham; J Wu; MA O'Shaughnessy; K Molina; A Broniscer; SL Spunt; I Luckett; CF Stewart; PJ Houghton; RJ Gilbertson; WL Furman,2007,,0.9875190258026123,,
134,26800393,"TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.",IM Ghobrial; DS Siegel; R Vij; JG Berdeja; PG Richardson; R Neuwirth; CG Patel; F Zohren; JL Wolf,2016,,0.98748779296875,,
135,15136596,"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.",E Raymond; J Alexandre; S Faivre; K Vera; E Materman; J Boni; C Leister; J Korth-Bradley; A Hanauske; JP Armand,2004,,0.9874788522720337,,
136,19571778,Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients.,P Marquet; F Saint-Marcoux; A Prémaud; FL Sauvage; E Jaqz-Aigrain; C Knoop; Y Lebranchu; M Tiberi; I Domke; J Debord,2009,,0.9874260425567627,PMC2925205,
137,22664810,Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.,AS Thakkar; AD Abhyankar; SI Dani; DN Banker; PI Singh; SA Parmar; AA Mehta,2012,,0.9873215556144714,PMC3860837,
138,15996252,Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure.,G Filler; T Womiloju; J Feber; N Lepage; U Christians,2005,,0.9870829582214355,,
139,11557912,Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.,JM Kovarik; CH Hsu; L McMahon; S Berthier; C Rordorf,2001,,0.9870266318321228,,
140,22935583,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.",A Naing; C Aghajanian; E Raymond; D Olmos; G Schwartz; E Oelmann; L Grinsted; W Burke; R Taylor; S Kaye; R Kurzrock; U Banerji,2012,,0.9869822859764099,PMC3461162,
141,19656203,Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.,CR Felipe; SI Park; PG Pinheiro-Machado; R Garcia; DE Casarini; S Moreira; H Tedesco-Silva; JO Medina-Pestana,2009,,0.9869505763053894,,
142,25805799,First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.,B Basu; E Dean; M Puglisi; A Greystoke; M Ong; W Burke; M Cavallin; G Bigley; C Womack; EA Harrington; S Green; E Oelmann; JS de Bono; M Ranson; U Banerji,2015,,0.9867525100708008,PMC4512239,
143,24089446,Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.,AM Gonzalez-Angulo; F Meric-Bernstam; S Chawla; G Falchook; D Hong; A Akcakanat; H Chen; A Naing; S Fu; J Wheler; S Moulder; T Helgason; S Li; I Elias; N Desai; R Kurzrock,2013,,0.9865700602531433,PMC3935482,
144,23860641,"A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.",I Diaz-Padilla; H Hirte; AM Oza; BA Clarke; B Cohen; M Reedjik; T Zhang; S Kamel-Reid; SP Ivy; SJ Hotte; AA Razak; EX Chen; I Brana; M Wizemann; L Wang; LL Siu; PL Bedard,2013,,0.9865028858184814,PMC3771370,PK - None | Study Population - Table 1
145,14550821,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.",JM Kovarik; H Eisen; R Dorent; D Mancini; M Vigano; M Rouilly; CH Hsu; C Rordorf,2003,,0.9864270091056824,,
146,15785960,Effect of multiple-dose erythromycin on everolimus pharmacokinetics.,JM Kovarik; D Beyer; MN Bizot; Q Jiang; M Shenouda; RL Schmouder,2005,,0.9862868189811707,,
147,16418694,Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose.,LY Leung; HK Lim; MW Abell; JJ Zimmerman,2006,,0.9858621954917908,,
148,23887441,Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer.,K Wu; EE Cohen; LK House; J Ramírez; W Zhang; MJ Ratain; RR Bies,2012,,0.9858524799346924,PMC3600722,
149,19817503,Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.,FT Musuamba; A Rousseau; JL Bosmans; JJ Senessael; J Cumps; P Marquet; P Wallemacq; RK Verbeeck,2009,,0.9857126474380493,,
150,18218785,Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment.,JJ Zimmerman; A Patat; V Parks; R Moirand; K Matschke,2008,,0.9856619238853455,,
151,9263380,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients.,C Brattström; J Säwe; G Tydén; G Herlenius; K Claesson; J Zimmerman; CG Groth,1997,,0.9854925274848938,,
152,26019185,"Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.",PY Wen; A Omuro; MS Ahluwalia; HM Fathallah-Shaykh; N Mohile; JJ Lager; AD Laird; J Tang; J Jiang; C Egile; TF Cloughesy,2015,PI3K/mTOR; glioblastoma; pharmacodynamics; pharmacokinetics; temozolomide,0.985473096370697,PMC4588757,
153,24300398,Pharmacokinetic Evaluation of a DSPE-PEG2000 Micellar Formulation of Ridaforolimus in Rat.,CM Remsberg; Y Zhao; JK Takemoto; RM Bertram; NM Davies; ML Forrest,2012,,0.9852418303489685,PMC3834941,PK - Table 1 | Study Population - None
154,22357447,"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.",B Markman; J Tabernero; I Krop; GI Shapiro; L Siu; LC Chen; M Mita; M Melendez Cuero; S Stutvoet; D Birle; Ö Anak; W Hackl; J Baselga,2012,,0.9851614236831665,,
155,27781420,Circadian pharmacokinetics and limited sampling strategy of everolimus in heart transplant patients .,Y Terada; K Wada; S Matsuda; T Kuwahara; A Kawabata; M Takada; T Watanabe; S Nakajima; T Sato; O Seguchi; M Yanase; N Fukushima; T Nakatani,2017,,0.985044538974762,,
156,16303008,Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation.,D Cattaneo; S Merlini; S Zenoni; S Baldelli; E Gotti; G Remuzzi; N Perico,2005,,0.9849949479103088,,
157,27185573,Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours.,D Frappaz; SM Federico; AD Pearson; L Gore; ME Macy; SG DuBois; I Aerts; R Iannone; R Geschwindt; A Van Schanke; R Wang; B Geoerger,2016,Dalotuzumab; IGF1-R; Paediatrics; Pharmacokinetics; Phase 1; Ridaforolimus; mTOR,0.9849704504013062,,
158,16027400,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations.,PA Jacobson; KG Green; BJ Hering,2005,,0.9844724535942078,,
159,22182476,Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation.,C Junghanss; S Rathsack; R Wacke; V Weirich; H Vogel; B Drewelow; S Mueller; S Altmann; M Freund; S Lange,2012,,0.9841539263725281,,
160,12200787,"Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.",AK Jain; R Venkataramanan; JA Fridell; M Gadomski; LM Shaw; M Ragni; M Korecka; J Fung,2002,,0.9837794899940491,,
161,23921574,"Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).",HJ Meulenbeld; JS de Bono; ST Tagawa; YE Whang; X Li; KH Heath; AS Zandvliet; SW Ebbinghaus; GR Hudes; R de Wit,2013,,0.9833863377571106,,
162,28762135,Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.,RB Verheijen; F Atrafi; JHM Schellens; JH Beijnen; ADR Huitema; RHJ Mathijssen; N Steeghs,2018,,0.9831907153129578,PMC5904242,
163,28727815,"Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.",T Pascual; M Apellániz-Ruiz; C Pernaut; C Cueto-Felgueroso; P Villalba; C Álvarez; L Manso; L Inglada-Pérez; M Robledo; C Rodríguez-Antona; E Ciruelos,2017,,0.9830617904663086,PMC5519037,PK - None | Study Population - Table 2
164,20335831,Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.,J Pascual; D del Castillo; M Cabello; L Pallardó; JM Grinyó; AM Fernández; M Brunet,2010,,0.9828884601593018,,
165,31190275,"Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers.",H Minami; Y Fujiwara; K Muro; M Sato; A Moriya,2019,BGT226; PI3K; Pharmacodynamics; Pharmacokinetics; mTOR,0.9824527502059937,,
166,9443858,"Species differences in sirolimus stability in humans, rabbits, and rats.",GM Ferron; WJ Jusko,1998,,0.9822213053703308,,
167,33092063,SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.,S Jannier; V Kemmel; C Sebastia Sancho; A Chammas; AN Sabo; E Pencreach; F Farace; MP Chenard; B Lhermitte; B Geoerger; I Aerts; D Frappaz; P Leblond; N André; S Ducassou; N Corradini; AI Bertozzi; E Guérin; F Vincent; M Velten; N Entz-Werle,2020,HIF1; intra-tumor hypoxia; mTor; pediatric refractory cancers,0.9822079539299011,PMC7656302,
168,25467181,A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.,M Fouladi; JP Perentesis; LM Wagner; AA Vinks; JM Reid; C Ahern; G Thomas; CA Mercer; DA Krueger; PJ Houghton; LA Doyle; H Chen; B Weigel; SM Blaney,2015,,0.9821550846099854,PMC4454739,
169,12021624,A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.,VC McAlister; K Mahalati; KM Peltekian; A Fraser; AS MacDonald,2002,,0.9819137454032898,,
170,28750271,"Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.",E Angevin; PA Cassier; A Italiano; A Gonçalves; A Gazzah; C Terret; M Toulmonde; G Gravis; A Varga; C Parlavecchio; A Paci; V Poinsignon; JC Soria; D Drubay; A Hollebecque,2017,Drug development; Dual p70S6K/AKT inhibition; Gemcitabine; LY2780301; Molecular alterations; Molecular screening; PI3K/AKT/mTOR pathway; PTEN; Phase I,0.9818844199180603,,
171,15637533,Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.,JP Boni; C Leister; G Bender; V Fitzpatrick; N Twine; J Stover; A Dorner; F Immermann; ME Burczynski,2005,,0.9818785786628723,,
172,24122637,Favorable pharmacokinetics of biolimus A9 after deployment of Nobori stent for coronary artery disease: insights from Nobori PK study in Japanese subjects.,M Nakamura; Y Otsuka; Y Ueda; K Mitsudo,2012,,0.9818593859672546,,
173,25003665,Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.,J Martin-Liberal; M Gil-Martín; M Sáinz-Jaspeado; N Gonzalo; R Rigo; H Colom; C Muñoz; OM Tirado; X García del Muro,2014,,0.9817905426025391,PMC4150275,"PK - None | Study Population - Table 2, Table 4"
174,18926156,Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.,M Wiemer; A Seth; P Chandra; J Neuzner; G Richardt; JJ Piek; M Desaga; C Macaya; CJ Bol; K Miquel-Hebert; K De Roeck; PW Serruys,2008,,0.9816267490386963,,
175,10688254,Pharmacokinetics and metabolism of sirolimus.,HL Gallant-Haidner; DJ Trepanier; DG Freitag; RW Yatscoff,2000,,0.9815933108329773,,
176,16547714,Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus.,JM Kovarik; A Noe; Y Wang; I Mueller; G DeNucci; RL Schmouder,2006,,0.9813863635063171,,
177,23211938,Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.,MM Mita; E Poplin; CD Britten; WD Tap; EH Rubin; BB Scott; L Berk; VM Rivera; JW Loewy; P Dodion; F Haluska; J Sarantopoulos; A Mita; A Tolcher,2013,,0.981181263923645,,
178,12777861,Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.,M Majewski; M Korecka; J Joergensen; L Fields; P Kossev; W Schuler; L Shaw; MA Wasik,2003,,0.9811674356460571,,
179,16160599,Comparison of pharmacokinetics of the sirolimus-eluting stent in Japanese patients with those in American patients.,Y Otsuka; M Nakamura; S Yasuda; K Kozuma; H Hara; I Morii; A Kawamura; K Sase; S Miyazaki,2005,,0.9811024069786072,,
180,15316094,Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.,K Budde; HH Neumayer; G Lehne; M Winkler; IA Hauser; A Lison; L Fritsche; JP Soulillou; P Fauchald; J Dantal; ,2004,,0.9810692667961121,,
181,23265712,A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.,SP Choo; B Chowbay; QS Ng; CH Thng; C Lim; S Hartono; TS Koh; H Huynh; D Poon; MK Ang; S Chang; HC Toh,2013,,0.9808996915817261,,
182,19016466,The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.,M Ostojic; D Sagic; R Jung; YL Zhang; M Nedeljkovic; L Mangovski; S Stojkovic; D Debeljacki; M Colic; B Beleslin; B Milosavljevic; D Orlic; D Topic; N Karanovic; D Paunovic; U Christians; ,2008,,0.9802641868591309,PMC2597665,
183,21107682,Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.,G Jerusalem; A Fasolo; V Dieras; F Cardoso; J Bergh; L Vittori; Y Zhang; C Massacesi; T Sahmoud; L Gianni,2011,,0.9802026748657227,,
184,32335374,Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.,X Sheng; X Yan; Z Chi; C Cui; L Si; B Tang; S Li; L Mao; B Lian; X Wang; X Bai; L Zhou; Y Kong; J Dai; L Ding; L Mao; J Guo,2020,CM082; Combination therapy; Everolimus; Renal cell carcinoma; Vorolanib,0.9793736934661865,PMC7184160,PK - None | Study Population - Table 1
185,20674213,"Quantitative determination of sirolimus in dog blood using liquid chromatography-tandem mass spectrometry, and its applications to pharmacokinetic studies.",JH Lee; KH Cha; W Cho; J Park; HJ Park; Y Cho; SJ Hwang,2010,,0.9787838459014893,,
186,28357727,A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.,TM Wise-Draper; G Moorthy; MA Salkeni; NA Karim; HE Thomas; CA Mercer; MS Beg; S O'Gara; O Olowokure; H Fathallah; SC Kozma; G Thomas; O Rixe; P Desai; JC Morris,2017,,0.9780954122543335,PMC5447332,PK - Table 3 | Study Population - Table 1
187,30990905,"Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.",JB McCrea; S Macha; A Adedoyin; W Marshall; K Menzel; CR Cho; F Liu; T Zhao; V Levine; WK Kraft; E Yoon; D Panebianco; SA Stoch; M Iwamoto,2019,cytomegalovirus; drug-drug interaction; immunosuppressant; letermovir,0.9773483276367188,,
188,10051053,Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients.,B Kaplan; HU Meier-Kriesche; KL Napoli; BD Kahan,1999,,0.9772084951400757,,
189,24916546,A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.,A Wang-Gillam; N Thakkar; AC Lockhart; K Williams; M Baggstrom; M Naughton; R Suresh; C Ma; B Tan; W Lee; X Jiang; T Mwandoro; L Trull; S Belanger; AN Creekmore; F Gao; PM Fracasso; J Picus,2014,,0.9769933819770813,PMC4112045,PK - Table 5 | Study Population - Table 2
190,32788078,"Model-based assessment of pharmacokinetic changes of sunitinib, tacrolimus, and everolimus in a patient with metastatic renal cell carcinoma after renal transplantation.",T Ito; K Yamamoto; S Ogawa; J Furukawa; K Harada; M Fujisawa; T Omura; I Yano,2020,Bayesian analysis; Everolimus; Metastatic renal cell carcinoma; Renal transplantation; Sunitinib; Tacrolimus,0.9763409495353699,,
191,18482049,"Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.",CC Rogers; RR Alloway; JW Alexander; M Cardi; J Trofe; AA Vinks,2008,,0.9763408303260803,PMC3660730,
192,10551636,A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.,BD Kahan; RL Wong; C Carter; SH Katz; J Von Fellenberg; CT Van Buren; S Appel-Dingemanse,1999,,0.9753463864326477,,
193,20040005,Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.,Q Wang; W Pierson; P Sood; C Bol; L Cannon; P Gordon; J Saucedo; K Sudhir,2010,,0.9751644134521484,,
194,21538783,Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients.,Y Otsuka; S Saito; M Nakamura; H Shuto; K Mitsudo,2011,,0.9746143221855164,,
195,24402086,Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.,H Colom; N Lloberas; F Andreu; A Caldés; J Torras; F Oppenheimer; J Sanchez-Plumed; MA Gentil; DR Kuypers; M Brunet; H Ekberg; JM Grinyó,2014,,0.9745023846626282,,
196,22006179,A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.,S Moulder; G Gladish; J Ensor; AM Gonzalez-Angulo; M Cristofanilli; JL Murray; D Booser; SH Giordano; A Brewster; J Moore; E Rivera; GN Hortobagyi; HT Tran,2012,,0.9739678502082825,PMC3893000,
197,22662868,Tolerability and pharmacokinetics of intravitreal sirolimus.,S Mudumba; P Bezwada; H Takanaga; K Hosoi; T Tsuboi; K Ueda; K Kawazu; Y Ali; J Naor,2012,,0.9738498330116272,,
198,24859653,Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.,SR Carvalho; AB Watts; JI Peters; S Liu; S Hengsawas; MS Escotet-Espinoza; RO Williams,2014,Dry powder; Formulation delivery; Inhalation; Particle engineering; Pharmacokinetics; Rapamycin; Thin film freezing,0.9737308025360107,,
199,15946913,Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.,K Budde; L Fritsche; J Waiser; P Glander; T Slowinski; HH Neumayer; ,2005,,0.9736509919166565,,
200,25677784,"Determination of GDC-0980 (apitolisib), a small molecule dual phosphatidylinositide 3-kinase/mammalian target of rapamycin inhibitor in dog plasma by LC-MS/MS to support a GLP toxicology study.",X Ding; L Salphati; A Kim; E Morinello; L Wong; J Pang; S Percey; M Meng; S Reuschel; B Dean,2015,GDC-0980 (apitolisib); Good Laboratory Practice (GLP); LC-MS/MS; dual phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor; selected reaction monitoring,0.9735760688781738,,
201,32578154,"Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.",S Kondo; M Tajimi; T Funai; K Inoue; H Asou; VK Ranka; V Wacheck; T Doi,2020,Advanced malignancies; Dose-escalation study; Japanese patients; LY3023414; Safety,0.97325599193573,PMC7575488,PK - Table 3 | Study Population - Table 1
202,23659969,"A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.",L Gore; TM Trippett; HM Katzenstein; J Boklan; A Narendran; A Smith; ME Macy; K Rolla; ; N Narashimhan; RM Squillace; CD Turner; FG Haluska; M Nieder,2013,,0.9731060266494751,,
203,14629289,Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients.,JM Kovarik; J Dantal; G Civati; G Rizzo; M Rouilly; O Bettoni-Ristic; C Rordorf,2003,,0.9730719327926636,,
204,22850296,"Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation.",X Hu; C Lin; D Chen; J Zhang; Z Liu; W Wu; H Song,2012,,0.9728941917419434,,
205,20855840,Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.,A Perotti; A Locatelli; C Sessa; D Hess; L Viganò; G Capri; M Maur; T Cerny; S Cresta; F Rojo; J Albanell; S Marsoni; I Corradino; L Berk; VM Rivera; F Haluska; L Gianni,2010,,0.9727575778961182,,
206,30393943,Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.,RJ Deyell; B Wu; SR Rassekh; D Tu; Y Samson; A Fleming; E Bouffet; X Sun; J Powers; L Seymour; S Baruchel; DA Morgenstern,2019,antiangiogenesis-angiogenesis; mTOR; phase I; sirolimus; temsirolimus; vinblastine,0.9720850586891174,,
207,19784839,Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.,T O'Reilly; PM McSheehy; R Kawai; O Kretz; L McMahon; J Brueggen; A Bruelisauer; HP Gschwind; PR Allegrini; HA Lane,2010,,0.9719485640525818,,
208,28601972,"TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.",HA Burris; CD Kurkjian; L Hart; S Pant; PB Murphy; SF Jones; R Neuwirth; CG Patel; F Zohren; JR Infante,2017,Combination chemotherapy; MLN0128; Phase I; Solid tumors; TAK-228; TORC1/2 inhibitor,0.9716750979423523,,
209,11211186,Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients.,GA Levy; D Grant; K Paradis; J Campestrini; T Smith; JM Kovarik,2001,,0.9714176058769226,,
210,24061443,Racial comparisons of everolimus pharmacokinetics and pharmacodynamics in adult kidney transplant recipients.,DJ Taber; L Belk; H Meadows; N Pilch; J Fleming; T Srinivas; J McGillicuddy; C Bratton; K Chavin; P Baliga,2013,,0.9709474444389343,PMC4525070,
211,10594869,Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients.,PA Kelly; K Napoli; BD Kahan,1999,,0.9708277583122253,,
212,30211770,"(2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans.",G Collo; L Cavalleri; C Chiamulera; E Merlo Pich,2018,,0.9706341028213501,,
213,19783551,Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors.,I Okamoto; T Doi; A Ohtsu; M Miyazaki; A Tsuya; K Kurei; K Kobayashi; K Nakagawa,2010,,0.9702780842781067,PMC2800315,PK - Table 3 | Study Population - Table 1
214,26686201,A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).,JW Chiu; SJ Hotte; CK Kollmannsberger; DJ Renouf; DW Cescon; D Hedley; S Chow; J Moscow; Z Chen; M Perry; I Diaz-Padilla; D Tan; H Hirte; E McWhirter; H Chen; LL Siu; PL Bedard,2016,AMG386; Combination therapy; Phase 1; Temsirolimus; Trebananib,0.9698571562767029,PMC4718956,PK - None | Study Population - Table 1
215,19015855,"Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.",J Boni; R Abbas; C Leister; J Burns; R Jordan; M Hoffmann; W DeMaio; B Hug,2009,,0.9696163535118103,,
216,16291711,Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment.,JJ Zimmerman; KC Lasseter; HK Lim; D Harper; SC Dilzer; V Parker; K Matschke,2005,,0.9691573977470398,,
217,28000286,Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group.,T Mizuno; T Fukuda; U Christians; JP Perentesis; M Fouladi; AA Vinks,2017,mTOR inhibitor; paediatrics; population pharmacokinetics; sirolimus; temsirolimus,0.9687098860740662,PMC5401981,
218,20543980,Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.,MC Paoloni; C Mazcko; E Fox; T Fan; S Lana; W Kisseberth; DM Vail; K Nuckolls; T Osborne; S Yalkowsy; D Gustafson; Y Yu; L Cao; C Khanna,2010,,0.9683342576026917,PMC2882366,PK - Table 4 | Study Population - Table 3
219,32089640,Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).,A Kim; Y Lu; SH Okuno; D Reinke; O Maertens; J Perentesis; M Basu; PL Wolters; T De Raedt; S Chawla; R Chugh; BA Van Tine; G O'Sullivan; A Chen; K Cichowski; BC Widemann,2020,,0.9682164788246155,PMC7013290,
220,25103371,Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.,NF Saba; SJ Hurwitz; K Magliocca; S Kim; TK Owonikoko; D Harvey; SS Ramalingam; Z Chen; J Rogerio; J Mendel; SA Kono; C Lewis; AY Chen; K Higgins; M El-Deiry; T Wadsworth; JJ Beitler; DM Shin; SY Sun; FR Khuri,2014,"everolimus in head and neck cancer; everolimus in squamous cell carcinoma; everolimus, cetuximab, and carboplatin; mTOR inhibition in head and neck cancer; mTOR inhibition in squamous cell carcinoma; pharmacokinetics, and NONMEM",0.9656596183776855,,
221,33547201,A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.,MD DeWire; C Fuller; O Campagne; T Lin; H Pan; T Young Poussaint; PA Baxter; EI Hwang; A Bukowinski; K Dorris; L Hoffman; AJ Waanders; MA Karajannis; CF Stewart; A Onar-Thomas; M Fouladi; IJ Dunkel,2021,,0.9651561975479126,PMC8132306,
222,15292713,Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.,SM Chang; J Kuhn; P Wen; H Greenberg; D Schiff; C Conrad; K Fink; HI Robins; T Cloughesy; L De Angelis; J Razier; K Hess; J Dancey; MD Prados; ,2004,,0.9649204015731812,,
223,19901013,Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.,C Sessa; D Tosi; L Viganò; J Albanell; D Hess; M Maur; S Cresta; A Locatelli; R Angst; F Rojo; N Coceani; VM Rivera; L Berk; F Haluska; L Gianni,2010,,0.9643526673316956,,
224,30016392,Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.,B Basu; MG Krebs; R Sundar; RH Wilson; J Spicer; R Jones; M Brada; DC Talbot; N Steele; AH Ingles Garces; W Brugger; EA Harrington; J Evans; E Hall; H Tovey; FM de Oliveira; S Carreira; K Swales; R Ruddle; FI Raynaud; B Purchase; JC Dawes; M Parmar; AJ Turner; N Tunariu; S Banerjee; JS de Bono; U Banerji,2018,,0.9641144871711731,PMC6158767,PK - Table 2 | Study Population - None
225,17164687,12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics.,KL Napoli,2006,,0.9637455344200134,,
226,15518745,Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.,SC Chueh; SM Wang; MK Lai; J Chen,2004,,0.9635357856750488,,
227,12000472,Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients.,R Van Damme-Lombaerts; NA Webb; PF Hoyer; J Mahan; J Lemire; R Ettenger; L McMahon; N Cambon; R Boger; JM Kovarik; ,2002,,0.9630545973777771,,
228,33686452,"A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.",A Azaro; C Massard; WD Tap; PA Cassier; J Merchan; A Italiano; B Anderson; E Yuen; D Yu; G Oakley; KA Benhadji; S Pant,2021,Abemaciclib; Crenigacestat; LY3039478; Metastatic cancer; Notch inhibition; Phase 1,0.9626564979553223,,
229,22696419,Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.,L Salphati; J Pang; EG Plise; LB Lee; AG Olivero; WW Prior; D Sampath; S Wong; X Zhang,2012,,0.962432861328125,,
230,16980022,Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.,CH Wang; NK Chou; FL Wu; WJ Ko; CI Tsao; NH Chi; RB Hsu; SS Wang,2006,,0.9622217416763306,,
231,34041638,Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.,M Fukudo; K Ishibashi; M Kitada,2021,Breast cancer; Everolimus; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring,0.9621821641921997,,
232,26150050,Evaluation of 6β-Hydroxycortisol and 6β-Hydroxycortisone as Biomarkers for Cytochrome P450 3A Activity: Insight into Their Predictive Value for Estimating Oral Immunosuppressant Metabolism.,X Luo; L Zheng; N Cai; Q Liu; S Yang; X He; Z Cheng,2015,biopharmaceutics classification system; cytochrome P450; drug metabolizing enzymes; pharmacokinetics; phenotype,0.9619384407997131,,
233,26543771,CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.,Y Li; L Yan; Y Shi; Y Bai; J Tang; L Wang,2015,CYP3A5 and ABCB1; Pharmacokinetics; Polymorphism; Renal transplantation; Sirolimus; Tacrolimus,0.9606642723083496,PMC4628029,PK - None | Study Population - Table 1
234,26580489,Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.,K Budde; BA Zonnenberg; M Frost; W Cheung; S Urva; T Brechenmacher; K Stein; D Chen; JC Kingswood; JJ Bissler,2016,VEGF-D; angiomyolipoma; biomarkers; collagen-IV; lymphangioleiomyomatosis; tuberous sclerosis complex,0.9605762958526611,PMC4834586,
235,19415181,"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.",JC Buckner; B Forouzesh; C Erlichman; M Hidalgo; JP Boni; G Dukart; A Berkenblit; EK Rowinsky,2010,,0.9602295756340027,,
236,10823378,Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.,A MacDonald; J Scarola; JT Burke; JJ Zimmerman,2000,,0.9601471424102783,,
237,31244112,"(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.",D Rageot; T Bohnacker; E Keles; JA McPhail; RM Hoffmann; A Melone; C Borsari; R Sriramaratnam; AM Sele; F Beaufils; P Hebeisen; D Fabbro; P Hillmann; JE Burke; MP Wymann,2019,,0.959501326084137,,
238,17431753,Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake.,R Laplanche; GM Meno-Tetang; R Kawai,2007,,0.9594447612762451,,
239,33496801,A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.,S Sarkar; B Tran; L Horvath; M Lam; P Savas; P Grimison; JR Whittle; JC Kuo; N Signal; D Edmonds; P Hogg; D Rischin; J Desai; A Hamilton,2021,Clinical trial; Mitochondrial inhibitor; Novel arsenical compound; PENAO; Phase I,0.9570168852806091,,
240,23131698,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.",F Lemaitre; E Bezian; L Goldwirt; C Fernandez; R Farinotti; S Varnous; S Urien; M Antignac,2012,,0.956987202167511,,
241,25223651,Reduced sirolimus systemic exposure and improved bioresorbable polymer properties: new allies for the treatment of patients with coronary artery disease.,S Stojkovic; AN Neskovic; Z Mehmedbegovic; S Kafedzic; M Ostojic; M Nedeljkovic; D Orlic; B Ilisic; I Ilic; A Aleksic; M Cerovic; I Nikolajevic; A Vlahovic-Stipac; Z Stajic; B Putnikovic; M Hamilos,2015,bioresorbable co-polymer; drug-eluting stent; sirolimus,0.956313967704773,,
242,21252987,Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.,SS Farag; LL Wood; JE Schwartz; S Srivastava; RP Nelson; MJ Robertson; R Abonour; A Secrest; E Cox; J Baute; C Sullivan; K Kane; DR Jones,2011,,0.9561180472373962,,
243,21690471,Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.,SL Spunt; SA Grupp; TA Vik; VM Santana; DJ Greenblatt; J Clancy; A Berkenblit; M Krygowski; R Ananthakrishnan; JP Boni; RJ Gilbertson,2011,,0.9560747146606445,PMC3138720,
244,17577220,Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.,DT Milton; GJ Riely; CG Azzoli; JE Gomez; RT Heelan; MG Kris; LM Krug; W Pao; B Pizzo; NA Rizvi; VA Miller,2007,,0.9554806351661682,,
245,26174223,A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.,R Kanesvaran; K Watt; JD Turnbull; AJ Armstrong; MC Wolkowiez; DJ George,2015,Combination; Kidney cancer; Metastatic; VEGF TKI; mTOR inhibitor,0.9550382494926453,PMC4754968,
246,22162657,Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.,MS Kim; JS Kim; HJ Park; WK Cho; KH Cha; SJ Hwang,2011,bioavailability; nanoparticles; sirolimus; solubility; supercritical antisolvent,0.954204797744751,PMC3230567,
247,28194539,Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.,M Mita; S Fu; SA Piha-Paul; F Janku; A Mita; R Natale; W Guo; C Zhao; R Kurzrock; A Naing,2017,MAPK; MEK; Pimasertib; Safety; Solid tumors; Temsirolimus,0.9541183710098267,PMC5935457,
248,32285686,UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study.,H Wang; T Wang; Z Wang; Z Du; Q Zhao; J Jiang; P Hu,2020,FP208; UHPLC–MS/MS; first-in-human; human plasma; mTOR inhibitor; mTORC1; mTORC2; pharmacokinetics; protein precipitation method; validation,0.953658938407898,,
249,11808830,Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction.,JM Kovarik; J Kalbag; J Figueiredo; M Rouilly; OL Frazier; C Rordorf,2002,,0.9526283740997314,,
250,18812562,Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.,F Pea; U Baccarani; M Tavio; P Cojutti; GL Adani; A Londero; M Baraldo; L Franceschi; M Furlanut; P Viale,2008,,0.9520860314369202,,
251,17048977,Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.,N Djebli; A Rousseau; G Hoizey; JP Rerolle; O Toupance; Y Le Meur; P Marquet,2006,,0.9501438140869141,,
252,23641156,Optimized formulation of solid self-microemulsifying sirolimus delivery systems.,W Cho; MS Kim; JS Kim; J Park; HJ Park; KH Cha; JS Park; SJ Hwang,2013,bioavailability; microemulsion; self-emulsifying drug delivery systems; sirolimus; solubility; stability,0.9500723481178284,PMC3639716,
253,21900840,"Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.",J Vansteenkiste; B Solomon; M Boyer; J Wolf; N Miller; L Di Scala; I Pylvaenaeinen; K Petrovic; S Dimitrijevic; B Anrys; E Laack,2011,,0.9500307440757751,,
254,27206639,A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I.,AC de Melo; R Grazziotin-Reisner; F Erlich; MS Fontes Dias; G Moralez; M Carneiro; ÁH Ingles Garces; FV Guerra Alves; B Novaes Neto; M Fuchshuber-Moraes; J Morando; G Suarez-Kurtz; CG Ferreira,2016,Cervix cancer; Cisplatin; Everolimus; Phase I; Radiotherapy,0.949964702129364,,
255,15831774,Blood concentrations of everolimus are markedly increased by ketoconazole.,JM Kovarik; D Beyer; MN Bizot; Q Jiang; M Shenouda; RL Schmouder,2005,,0.9497066736221313,,
256,24456794,"A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.",A Hollebecque; N Houédé; EE Cohen; C Massard; A Italiano; P Westwood; W Bumgardner; J Miller; LH Brail; KA Benhadji; JC Soria,2014,Erlotinib; Everolimus; LY2584702 tosylate; p70 S6 kinase inhibitor,0.9489671587944031,,
257,26113676,Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.,HJ Goldberg; S Harari; V Cottin; IO Rosas; E Peters; S Biswal; Y Cheng; S Khindri; JM Kovarik; S Ma; FX McCormack; EP Henske,2015,,0.9467986822128296,,
258,30537529,Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia.,T Mizuno; MM O'Brien; AA Vinks,2019,Acute lymphoblastic leukemia; Model-informed precision dosing; Pediatrics; Pharmacokinetics; Sirolimus,0.9465790390968323,,
259,30446785,A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors.,M Toyoda; K Watanabe; T Amagasaki; K Natsume; H Takeuchi; C Quadt; K Shirao; H Minami,2019,BEZ235; Inhibitor; PI3K; Phase I; mTOR,0.9459250569343567,PMC6394493,PK - Table 6 | Study Population - Table 1
260,27293194,Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.,FT Awan; L Gore; L Gao; J Sharma; J Lager; LJ Costa,2016,PI3K/mTOR; chronic lymphocytic leukaemia; non-Hodgkin lymphoma; pharmacokinetics; rituximab,0.9458961486816406,,
261,33467464,Development and Validation of a Bioanalytical LC-MS/MS Method for Simultaneous Determination of Sirolimus in Porcine Whole Blood and Lung Tissue and Pharmacokinetic Application with Coronary Stents.,TT Nguyen; VA Duong; DK Vo; J Jo; HJ Maeng,2021,LC-MS/MS; bio-distribution; lung tissue; pharmacokinetic; sirolimus; validation; whole blood,0.945213794708252,PMC7829871,PK - Table 6 | Study Population - None
262,23396259,Supersaturatable formulations for the enhanced oral absorption of sirolimus.,MS Kim; JS Kim; W Cho; KH Cha; HJ Park; J Park; SJ Hwang,2013,,0.9441074132919312,,
263,23394126,"Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).",CS Takeuchi; BG Kim; CM Blazey; S Ma; HW Johnson; NK Anand; A Arcalas; TG Baik; CA Buhr; J Cannoy; S Epshteyn; A Joshi; K Lara; MS Lee; L Wang; JW Leahy; JM Nuss; N Aay; R Aoyama; P Foster; J Lee; I Lehoux; N Munagala; A Plonowski; S Rajan; J Woolfrey; K Yamaguchi; P Lamb; N Miller,2013,,0.944000244140625,,
264,18641543,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.,MJ Figurski; A Nawrocki; MD Pescovitz; R Bouw; LM Shaw,2008,,0.9423938989639282,,
265,32720301,Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients.,TC Zwart; DJAR Moes; PJM van der Boog; NP van Erp; JW de Fijter; HJ Guchelaar; RJ Keizer; R Ter Heine,2021,,0.9418338537216187,PMC7862213,
266,26497877,Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.,K Blackwell; H Burris; P Gomez; N Lynn Henry; S Isakoff; F Campana; L Gao; J Jiang; S Macé; SM Tolaney,2015,HER2-negative; Hormone-receptor-positive metastatic breast cancer; PI3K; Pilaralisib; Voxtalisib,0.9417151212692261,,
267,25162215,Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.,C Emoto; T Fukuda; T Mizuno; S Cox; B Schniedewind; U Christians; BC Widemann; MJ Fisher; B Weiss; J Perentesis; AA Vinks,2015,,0.9404667615890503,,
268,21645967,"Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.",DJ Gallagher; H Al-Ahmadie; I Ostrovnaya; SR Gerst; A Regazzi; I Garcia-Grossman; J Riches; SK Gounder; AM Flaherty; A Trout; MI Milowsky; DF Bajorin,2011,,0.9393550753593445,,
269,33995061,Population Pharmacokinetics and Initial Dose Optimization of Sirolimus Improving Drug Blood Level for Seizure Control in Pediatric Patients With Tuberous Sclerosis Complex.,X Chen; D Wang; L Zhu; J Lu; Y Huang; G Wang; Y Zhu; Q Ye; Y Wang; H Xu; Z Li,2021,initial dose optimization; population pharmacokinetics; seizure control; sirolimus; tuberous sclerosis complex,0.9386304616928101,PMC8114543,PK - TABLE 2 | Study Population - TABLE 1
270,10220493,Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.,A Crowe; A Bruelisauer; L Duerr; P Guntz; M Lemaire,1999,,0.9374665021896362,,
271,18074760,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial.",G Marcelín-Jiménez; A García-González; AP Angeles-Moreno; L Contreras-Zavala; L Rivera; M Morales,2007,,0.937092661857605,,
272,14748618,Clinical pharmacokinetics of everolimus.,GI Kirchner; I Meier-Wiedenbach; MP Manns,2004,,0.9364546537399292,,
273,21168621,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach.,V Sumethkul; P Tankee; P Chalermsanyakorn; S Jirasiritham,2010,,0.9361282587051392,,
274,28245187,"Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.",C Rodríguez-Jiménez; M García-Saiz; L Pérez-Tamajón; E Salido; A Torres,2017,,0.9357746839523315,,
275,14990647,"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.",MB Atkins; M Hidalgo; WM Stadler; TF Logan; JP Dutcher; GR Hudes; Y Park; SH Liou; B Marshall; JP Boni; G Dukart; ML Sherman,2004,,0.9352495074272156,,
276,17038875,Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids.,H Zahir; AM Keogh; F Akhlaghi,2006,,0.9336613416671753,,
277,19228743,"A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.",CM Hartford; AA Desai; L Janisch; T Karrison; VM Rivera; L Berk; JW Loewy; H Kindler; WM Stadler; HL Knowles; C Bedrosian; MJ Ratain,2009,,0.932597815990448,PMC3147153,
278,11571449,Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.,R Sindhi; S Webber; R Venkataramanan; W McGhee; S Phillips; A Smith; C Baird; K Iurlano; G Mazariegos; B Cooperstone; DW Holt; A Zeevi; JJ Fung; J Reyes,2001,,0.9307312369346619,,
279,18458675,Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.,JP Boni; C Leister; J Burns; B Hug,2008,,0.9288476705551147,PMC2410110,PK - Table 2 | Study Population - Table 1
280,29574974,A pharmacological rationale for improved everolimus dosing in oncology and transplant patients.,R Ter Heine; NP van Erp; HJ Guchelaar; JW de Fijter; MEJ Reinders; CM van Herpen; DM Burger; DJAR Moes,2018,cancer; dose individualization; everolimus; nonmem; population pharmacokinetics; transplant,0.9283575415611267,PMC6005589,
281,25300360,Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies.,YW Hsieh; CY Huang; SY Yang; YH Peng; CP Yu; PD Chao; YC Hou,2014,,0.9280294179916382,PMC5377466,PK - Table 1 | Study Population - None
282,31244435,"Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients.",Z Wang; M Zheng; H Yang; Z Han; J Tao; H Chen; L Sun; M Guo; L Wang; R Tan; JF Wei; M Gu,2019,"Tacrolimus; haplotype; kidney transplantation; pharmacogenetics; pharmacokinetics; single nucleotide polymorphisms; target
sequencing.",0.9277772307395935,,
283,12270379,Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients.,G Kirchner; L Mueller; M Winkler; M Loss; F Roechte; M Deters; U Christians; V Kaever; J Klempnauer; K Sewing; M Manns,2002,,0.9270239472389221,,
284,9721433,"Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update.",DJ Trepanier; H Gallant; DF Legatt; RW Yatscoff,1998,,0.9266085028648376,,
285,26787751,"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.",SO Dolly; AJ Wagner; JC Bendell; HL Kindler; LM Krug; TY Seiwert; MG Zauderer; MP Lolkema; D Apt; RF Yeh; JO Fredrickson; JM Spoerke; H Koeppen; JA Ware; JO Lauchle; HA Burris; JS de Bono,2016,,0.9249245524406433,PMC4876928,
286,24965180,Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).,MJ Boers-Sonderen; CM van Herpen; WT van der Graaf; IM Desar; MG van der Logt; YM de Beer; PB Ottevanger; NP van Erp,2014,,0.9248761534690857,,
287,15114077,Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood.,MJ Barten; F Streit; M Boeger; S Dhein; A Tarnok; M Shipkova; VW Armstrong; FW Mohr; M Oellerich; JF Gummert,2004,,0.9238668084144592,,
288,22037923,"Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.",DA Reardon; PY Wen; WK Alfred Yung; L Berk; N Narasimhan; CD Turner; T Clackson; VM Rivera; MA Vogelbaum,2012,,0.9238172769546509,,
289,10221478,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.",B Hausen; K Boeke; GJ Berry; I Segarra; LZ Benet; U Christians; RE Morris,1999,,0.9230551719665527,,
290,9558125,Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions.,KL Napoli; ME Wang; SM Stepkowski; BD Kahan,1998,,0.9220527410507202,,
291,29992479,Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex.,FP Combes; G Baneyx; N Coello; P Zhu; W Sallas; H Yin; J Nedelman,2018,Count data; Everolimus; Non-linear mixed effect models; Population PK/PD; Seizures; Tuberous sclerosis complex,0.9217894077301025,,
292,24991838,Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.,R Rangwala; YC Chang; J Hu; KM Algazy; TL Evans; LA Fecher; LM Schuchter; DA Torigian; JT Panosian; AB Troxel; KS Tan; DF Heitjan; AM DeMichele; DJ Vaughn; M Redlinger; A Alavi; J Kaiser; L Pontiggia; LE Davis; PJ O'Dwyer; RK Amaravadi,2014,MTOR; autophagy; clinical trial; hydroxychloroquine; melanoma,0.9204840064048767,PMC4203516,
293,23134470,Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.,HS Shiah; CY Chen; CY Dai; CF Hsiao; YJ Lin; WC Su; JY Chang; J Whang-Peng; PW Lin; JD Huang; LT Chen,2013,,0.9204466938972473,,
294,27448924,"Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.",J Han; Y Chen; C Yang; T Liu; M Wang; H Xu; L Zhang; C Zheng; Y Song; J Zhu,2016,Anticancer; Dual inhibitors; Mammalian target of rapamycin (mTOR); Phosphoinositide 3-kinase (PI3K),0.9195877313613892,,
295,26375845,"Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.",U Vaishampayan; D Shevrin; M Stein; L Heilbrun; S Land; K Stark; J Li; B Dickow; E Heath; D Smith; J Fontana,2015,,0.9195110201835632,PMC6902637,
296,17203553,Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids.,H Zahir; A Keogh; F Akhlaghi,2006,,0.9186133146286011,,
297,28353583,Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.,A Noreikaitė; F Saint-Marcoux; P Marquet; E Kaduševičius; E Stankevičius,2017,,0.9185284376144409,PMC5380267,
298,21079958,A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).,KE Bullock; WP Petros; I Younis; HE Uronis; MA Morse; GC Blobe; SY Zafar; JP Gockerman; JJ Lager; R Truax; KL Meadows; LA Howard; MM O'Neill; G Broadwater; HI Hurwitz; JC Bendell,2011,,0.9185081124305725,PMC4086252,
299,21177764,Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.,R Quek; Q Wang; JA Morgan; GI Shapiro; JE Butrynski; N Ramaiya; T Huftalen; N Jederlinic; J Manola; AJ Wagner; GD Demetri; S George,2011,,0.9183239340782166,,
300,28424891,A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.,JR Infante; RB Cohen; KB Kim; HA Burris; G Curt; U Emeribe; D Clemett; HK Tomkinson; PM LoRusso,2017,Advanced solid tumors; Dose-escalation; Erlotinib; Selumetinib; Temsirolimus,0.9182566404342651,PMC5613062,PK - Table 4 | Study Population - Table 1
301,29068216,"Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor.",L Zhang; Z Liu; K Yang; C Kong; C Liu; H Chen; J Huang; F Qian,2017,NSCLC; angiogenesis; itraconazole; nanoparticle formulations; pharmacokinetics,0.9182302355766296,,
302,28625629,A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.,T Moran; R Palmero; M Provencio; A Insa; M Majem; N Reguart; J Bosch-Barrera; D Isla; EC Costa; C Lee; M Puig; S Kraemer; D Schnell; R Rosell,2017,Afatinib; Epidermal growth factor receptor; Non-small cell lung cancer; Sirolimus,0.9179298877716064,,
303,24368401,A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.,B Besse; RS Heist; VA Papadmitrakopoulou; DR Camidge; JT Beck; P Schmid; C Mulatero; N Miller; S Dimitrijevic; S Urva; I Pylvaenaeinen; K Petrovic; BE Johnson,2014,cisplatin; etoposide; everolimus; phase I; small-cell lung cancer,0.9177843928337097,,
304,25649370,Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.,MM Abu-Khalaf; MA Baumgart; SN Gettinger; I Doddamane; DP Tuck; S Hou; N Chen; C Sullivan; K Lezon-Geyda; D Zelterman; C Hatzis; H Deshpande; MP Digiovanna; M Azodi; PE Schwartz; LN Harris,2015,[18F]fludeoxyglucose positron emission tomography (FDG-PET); mammalian target of rapamycin (mTOR); nanoparticle albumin-bound paclitaxel (nab-paclitaxel); sirolimus; solid tumors,0.9145530462265015,,
305,25417855,Worsening pneumonitis due to a pharmacokinetic drug-drug interaction between everolimus and voriconazole in a renal transplant patient.,C Lecefel; P Eloy; B Chauvin; B Wyplosz; V Amilien; L Massias; AM Taburet; H Francois; V Furlan,2015,everolimus; interaction; pneumonitis; transplantation; voriconazole,0.9122818112373352,,
306,28616837,A phase Ib study of everolimus combined with metformin for patients with advanced cancer.,RJ Molenaar; T van de Venne; MJ Weterman; RA Mathot; HJ Klümpen; DJ Richel; JW Wilmink,2018,Cancer; Everolimus; Metformin; Pharmacokinetics; Safety; Toxicity,0.9105396866798401,PMC5805805,PK - Table 5 | Study Population - Table 2
307,24332451,Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology.,A Ravaud; SR Urva; K Grosch; WK Cheung; O Anak; DB Sellami,2014,Cancer; Efficacy; Everolimus; Pharmacokinetics; Safety,0.9102542400360107,,
308,28950146,PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.,M Guerin; K Rezai; N Isambert; M Campone; A Autret; J Pakradouni; M Provansal; J Camerlo; R Sabatier; F Bertucci; E Charafe-Jauffret; A Hervieu; JM Extra; P Viens; F Lokiec; JM Boher; A Gonçalves,2017,Breast cancer; Buparlisib; HER2-positive; Lapatinib; Trastuzumab-resistant,0.9100619554519653,,
309,23071263,Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.,A Thiery-Vuillemin; E Curtit; T Maurina; D Montange; C Succi; T NGuyen; S Kim; P Montcuquet; X Pivot; B Royer,2012,,0.9088959693908691,,
310,16815317,CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.,Y Le Meur; N Djebli; JC Szelag; G Hoizey; O Toupance; JP Rérolle; P Marquet,2006,,0.9076129198074341,,
311,16397287,A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection.,TH Mathew; C Van Buren; BD Kahan; K Butt; S Hariharan; JJ Zimmerman,2006,,0.9043927192687988,,
312,22160854,A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.,WP Mason; M Macneil; P Kavan; J Easaw; D Macdonald; B Thiessen; S Urva; Z Lwin; L McIntosh; E Eisenhauer,2012,,0.9034945368766785,,
313,24827931,Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.,M Stroh; J Talaty; P Sandhu; J McCrea; A Patnaik; A Tolcher; J Palcza; K Orford; S Breidinger; N Narasimhan; D Panebianco; R Lush; KP Papadopoulos; JA Wagner; M Trucksis; N Agrawal,2014,midazolam; pharmacokinetics; ridaforolimus,0.9025253653526306,,
314,22459565,Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.,T Decaens; A Luciani; E Itti; A Hulin; F Roudot-Thoraval; A Laurent; ES Zafrani; A Mallat; C Duvoux,2012,,0.9020945429801941,,
315,22843211,Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.,H Asahina; H Nokihara; N Yamamoto; Y Yamada; Y Tamura; K Honda; Y Seki; Y Tanabe; H Shimada; X Shi; T Tamura,2013,,0.9010058045387268,,
316,23676788,Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient.,H Shinke; S Hashi; R Kinoshita; R Taniguchi; M Sugimoto; K Matsubara; E Ogawa; M Sonoda; N Takada; A Yoshizawa; K Ogawa; S Okamoto; S Uemoto; S Masuda,2013,,0.9005985260009766,,
317,34347542,Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.,F Bautista; X Paoletti; J Rubino; C Brard; K Rezai; S Nebchi; N Andre; I Aerts; E De Carli; N van Eijkelenburg; E Thebaud; N Corradini; AS Defachelles; S Ducassou; RJ Morscher; G Vassal; B Geoerger,2021,,0.9001603722572327,,
318,32946190,Nanospheres encapsulated everolimus delivery into arterial wall-the tissue pharmacokinetics and vascular response experimental study.,K Milewski; A Bryła-Wojciechowska; PP Buszman; K Jelonek; M Kachel; P Gąsior; A Krauze; A Błachut; M Musiał-Kulik; A Tellez; SD Rousselle; RS Kiesz; J Kasperczyk; PE Buszman,2020,animal models; balloon angioplasty; coronary artery disease,0.8986486196517944,,
319,26298499,"The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.",MM Stec; KL Andrews; Y Bo; S Caenepeel; H Liao; J McCarter; EL Mullady; T San Miguel; R Subramanian; N Tamayo; DA Whittington; L Wang; T Wu; LP Zalameda; N Zhang; PE Hughes; MH Norman,2015,"Affinity pocket; Imidazo[1,2-a]pyridine; Kinase inhibitor; Phosphoinositide 3-kinase; Ribose pocket; mTOR",0.8981354832649231,,
320,24557436,Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer.,C Acevedo-Gadea; AD Santin; SA Higgins; S Urva; E Ratner; DA Silasi; M Azodi; T Rutherford; PE Schwartz; MM Abu-Khalaf,2014,,0.8976535201072693,,
321,33744643,Combined effect of citrulline and lactoserum on amino acid availability in aged rats.,P Jegatheesan; C Vicente; P Marquet de Rouge; N Neveux; R Ramassamy; S Magassa; C Aussel; A Raynaud-Simon; L Cynober; JP De Bandt,2021,Amino acid availability; Casein; Citrulline; Muscle; Whey,0.8960484266281128,,
322,31243774,Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report.,T Uno; K Wada; S Matsuda; M Ikura; H Takenaka; N Terakawa; A Oita; S Yokoyama; A Kawase; K Hosomi; M Takada,2019,,0.8957930207252502,PMC6710514,
323,21530655,Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with oral bioavailabilities in rats.,M Sun; X Zhai; K Xue; L Hu; X Yang; G Li; L Si,2011,,0.8947178721427917,,
324,10594471,Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.,HH Neumayer; K Paradis; A Korn; C Jean; L Fritsche; K Budde; M Winkler; V Kliem; R Pichlmayr; IA Hauser; K Burkhardt; AE Lison; I Barndt; S Appel-Dingemanse,1999,,0.8946356773376465,PMC2014362,
325,21045832,A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.,IM Desar; JN Timmer-Bonte; DM Burger; WT van der Graaf; CM van Herpen,2010,,0.894199013710022,PMC2994217,
326,25940522,Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial duct.,KJ Lee; W Seto; L Benson; RR Chaturvedi,2015,congenital heart disease; drug-eluting stent; ductus arteriosus; neonate; pharmacokinetics; sirolimus,0.8933406472206116,,
327,26020699,Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e.,Y Cho; ES Ha; IH Baek; MS Kim; CW Cho; SJ Hwang,2015,Eudragit® E; bioavailability; sirolimus; solid dispersion; supersaturation,0.8917019963264465,PMC6272523,PK - Table 3 | Study Population - None
328,21913034,A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.,MG Fury; E Sherman; S Haque; S Korte; D Lisa; R Shen; N Wu; D Pfister,2012,,0.8915399312973022,,
329,8623483,Pharmacokinetics of rapamycin.,RW Yatscoff,1996,,0.890255868434906,,
330,19963096,Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.,JP Boni; B Hug; C Leister; D Sonnichsen,2009,,0.8886266350746155,,
331,21898375,Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.,AM Molina; DR Feldman; MH Voss; MS Ginsberg; MS Baum; DR Brocks; PM Fischer; MJ Trinos; S Patil; RJ Motzer,2012,,0.8881711959838867,PMC3609026,
332,22624503,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients.,DJ Moes; RR Press; J den Hartigh; T van der Straaten; JW de Fijter; HJ Guchelaar,2012,,0.8878752589225769,,
333,28886476,Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study.,A Ravaud; C Gomez-Roca; MQ Picat; L Digue; C Chevreau; A Gimbert; E Chauzit; R Sitta; F Cornelis; J Asselineau; R Aziza; A Daste; C Quemener; J Baud; A Bikfalvi; D Pedenon-Périchout; A Doussau; M Molimard; JP Delord,2017,Axitinib; Everolimus; Phase I; Renal cell carcinoma; Solid tumours,0.8872735500335693,,
334,26836480,"Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.",JO Eloy; R Petrilli; JF Topan; HMR Antonio; JPA Barcellos; DL Chesca; LN Serafini; DG Tiezzi; RJ Lee; JM Marchetti,2016,Breast cancer; Co-loading; Liposomes; Paclitaxel; Rapamycin,0.8843907117843628,PMC4957969,
335,32815764,Initial dose recommendation for sirolimus in paediatric kaposiform haemangioendothelioma patients based on population pharmacokinetics and pharmacogenomics.,X Chen; DD Wang; H Xu; ZP Li,2020,CYP3A5 genotype; Initial dose recommendation; paediatric kaposiform haemangioendothelioma; pharmacogenomics; population pharmacokinetics; sirolimus,0.8842004537582397,PMC7444137,
336,26225230,Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants.,C Emoto; T Fukuda; TN Johnson; DM Adams; AA Vinks,2015,,0.8819065690040588,PMC4360665,PK - None | Study Population - Table 1
337,18671816,"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease.",W Reinisch; J Panés; M Lémann; S Schreiber; B Feagan; S Schmidt; GC Sturniolo; T Mikhailova; O Alexeeva; L Sanna; T Haas; S Korom; H Mayer,2008,,0.8814569711685181,,
338,32475067,"Dose-Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men.",T Hörbelt; AL Kahl; F Kolbe; S Hetze; B Wilde; O Witzke; M Schedlowski,2020,,0.8812441229820251,PMC7719391,PK - None | Study Population - None
339,32436621,Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.,L Nogova; C Mattonet; M Scheffler; M Taubert; M Gardizi; ML Sos; S Michels; RN Fischer; M Limburg; DSY Abdulla; T Persigehl; C Kobe; S Merkelbach-Bruse; J Franklin; H Backes; R Schnell; D Behringer; B Kaminsky; M Eichstaedt; C Stelzer; M Kinzig; F Sörgel; Y Tian; L Junge; AA Suleiman; S Frechen; D Rokitta; D Ouyang; U Fuhr; R Buettner; J Wolf,2020,FDG-PET; KRAS mutation; Phase-I trial; non-small-cell lung cancer; pharmacodynamics; pharmacokinetics; solid tumors,0.8774309754371643,PMC7367645,PK - Table 5 | Study Population - Table 1
340,21881915,Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.,AH Bryce; R Rao; J Sarkaria; JM Reid; Y Qi; R Qin; CD James; RB Jenkins; J Boni; C Erlichman; P Haluska,2012,,0.87742680311203,PMC3816525,
341,28205374,Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies.,T Mizuno; T Fukuda; C Emoto; PS Mobberley-Schuman; AM Hammill; DM Adams; AA Vinks,2017,"developmental pharmacology; mTOR inhibitor; pharmacometrics, model-based precision dosing",0.8761702179908752,,
342,17438408,"Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.",YW Chen; ML Smith; M Sheets; S Ballaron; JM Trevillyan; SE Burke; T Rosenberg; C Henry; R Wagner; J Bauch; K Marsh; TA Fey; G Hsieh; D Gauvin; KW Mollison; GW Carter; SW Djuric,2007,,0.8754953742027283,,
343,17038957,Safety and pharmacokinetics of sirolimus-eluting stents in the canine cerebral vasculature: 180 day assessment.,EI Levy; RA Hanel; FO Tio; DS Garlick; L Bailey; MR Cunningham; C Williard; D Sherman; JF Dooley; GA Kopia,2006,,0.8741962313652039,,
344,11750348,Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.,A Vathsala; YM Lu,2001,,0.8735908269882202,,
345,26003815,Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method.,T Solymosi; R Angi; O Basa-Dénes; S Ránky; Z Ötvös; H Glavinas; G Filipcsei; G Heltovics,2015,Continuous flow precipitation; Enhanced bioavailability; Sirolimus,0.8725259900093079,,
346,18332467,Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.,C Tanaka; T O'Reilly; JM Kovarik; N Shand; K Hazell; I Judson; E Raymond; S Zumstein-Mecker; C Stephan; A Boulay; M Hattenberger; G Thomas; HA Lane,2008,,0.8699361085891724,,
347,20166697,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",AM Venkatesan; CM Dehnhardt; E Delos Santos; Z Chen; O Dos Santos; S Ayral-Kaloustian; G Khafizova; N Brooijmans; R Mallon; I Hollander; L Feldberg; J Lucas; K Yu; J Gibbons; RT Abraham; I Chaudhary; TS Mansour,2010,,0.8698104619979858,,
348,31156343,Exploring Sirolimus Pharmacokinetic Variability Using Data Available from the Routine Clinical Care of Renal Transplant Patients - Population Pharmacokinetic Approach.,B Golubović; K Vučićević; D Radivojević; SV Kovačević; M Prostran; B Miljković,2019,aspartate aminotransferase; kidney transplantation; pharmacokinetics; sirolimus; therapeutic drug monitoring,0.8696945905685425,PMC6534959,
349,26472338,Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy.,DG Rizik; L Cannon; GW Stone; M Kennedy; K Piard-Ruster; P Staehr; SG Ellis; DJ Kereiakes,2015,,0.869322657585144,,
350,28923619,Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation.,V Sumethkul; P Tankee; S Worawichawong; S Jirasiritham,2017,,0.8687300086021423,,
351,21168674,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.,AO Doesch; S Mueller; M Konstandin; S Celik; C Erbel; A Kristen; L Frankenstein; A Koch; P Ehlermann; C Zugck; HA Katus,2010,,0.8673921823501587,,
352,22033322,"Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.",B Geoerger; MW Kieran; S Grupp; D Perek; J Clancy; M Krygowski; R Ananthakrishnan; JP Boni; A Berkenblit; SL Spunt,2012,,0.8672894239425659,PMC3539305,
353,8588238,"Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.",RW Yatscoff; P Wang; K Chan; D Hicks; J Zimmerman,1995,,0.8670160174369812,,
354,28035748,A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.,OJ Becher; SW Gilheeney; Y Khakoo; DC Lyden; S Haque; KC De Braganca; JM Kolesar; JT Huse; S Modak; LH Wexler; K Kramer; I Spasojevic; IJ Dunkel,2017,AKT; mTOR; perifosine; phase I clinical trials; temsirolimus,0.8655425310134888,,
355,16404634,"Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.",A Gupta; Y Dai; RR Vethanayagam; MF Hebert; KE Thummel; JD Unadkat; DD Ross; Q Mao,2006,,0.864353597164154,,
356,33667297,Development and Validation of an LC-MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats.,Y Chen; X Gao; R Gupta; J Ma; R Dere; D Liang; H Xie,2021,,0.8639151453971863,PMC8742608,
357,27095353,Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.,A Gupta; D Sharma; J Meena; S Pandya; M Sachan; S Kumar; K Singh; K Mitra; S Sharma; AK Panda; P Gupta; UD Gupta; A Misra,2016,autophagy; biodistribution; dry powder inhalation; macrophage targeting; microparticles; microspheres; pharmacokinetics; pulmonary drug delivery; tuberculosis,0.8636220693588257,,
358,16995863,A Bayesian approach for population pharmacokinetic modelling of sirolimus.,C Dansirikul; RG Morris; SE Tett; SB Duffull,2006,,0.8628148436546326,PMC1885149,
359,21825263,Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.,CC Hofmeister; X Yang; F Pichiorri; P Chen; DM Rozewski; AJ Johnson; S Lee; Z Liu; CL Garr; EM Hade; J Ji; LJ Schaaf; DM Benson; EH Kraut; WJ Hicks; KK Chan; CS Chen; SS Farag; MR Grever; JC Byrd; MA Phelps,2011,,0.8626389503479004,PMC3164245,
360,32637742,High nitrogen stainless steel drug-eluting stent - Assessment of pharmacokinetics and preclinical safety in vivo.,S Chen; Z Yao; Y Guan; H Yang; MB Shahzad; Y Wu; B Zhang; L Shen; K Yang,2020,Pharmacokinetics; Preclinical safety; Sirolimus-eluting stent; Tissue response,0.8624595999717712,PMC7317698,"PK - Table 1, Table 2, Table 3 | Study Population - None"
361,27310200,Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.,C Emoto; AA Vinks; T Fukuda,2016,,0.8611884117126465,,
362,16563975,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.,JM Kovarik; GI Snell; V Valentine; R Aris; CK Chan; H Schmidli; U Pirron,2006,,0.8610621094703674,,
363,23884207,Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content.,C Emoto; T Fukuda; S Cox; U Christians; AA Vinks,2013,,0.8604059815406799,PMC3731827,
364,22132130,Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system.,P Hadaczek; J Beyer; A Kells; W Narrow; W Bowers; HJ Federoff; J Forsayeth; KS Bankiewicz,2011,,0.8603737354278564,PMC3221672,PK - None | Study Population - None
365,25003829,Improved oral absorption and chemical stability of everolimus via preparation of solid dispersion using solvent wetting technique.,SW Jang; MJ Kang,2014,Everolimus; Oral absorption; Solid dispersion; Solvent wetting technique; Stability,0.8594068884849548,,
366,11316866,Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.,H Podder; SM Stepkowski; KL Napoli; J Clark; RR Verani; TC Chou; BD Kahan,2001,,0.8582417964935303,,
367,22290273,The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.,M Stroh; J Palcza; J McCrea; S Marsilio; S Breidinger; D Panebianco; A Johnson-Levonas; WK Kraft; K Orford; G Murphy; N Agrawal; M Trucksis; JA Wagner; M Iwamoto,2012,,0.8571295738220215,,
368,24674875,"Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.",F Toffalorio; G Spitaleri; C Catania; L Dal Zotto; C Noberasco; A Delmonte; M Santarpia; F Vecchio; V Brunelli; C Rampinelli; M Barberis; C Fumagalli; M Zucchetti; M Zangarini; T Diena; R Danesi; F de Braud; T De Pas,2014,,0.855548620223999,PMC3983818,
369,25359003,Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.,K Singh; L Stempora; RD Harvey; AD Kirk; CP Larsen; BR Blazar; LS Kean,2014,Basic (laboratory) research/science; T cell biology; immunobiology; immunosuppression/immune modulation; lymphocyte biology: trafficking; tolerance: experimental; translational research/science,0.8552834391593933,PMC4236286,
370,21387258,A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.,AL Harzstark; EJ Small; VK Weinberg; J Sun; CJ Ryan; AM Lin; L Fong; DR Brocks; JE Rosenberg,2011,,0.8534536361694336,,
371,26818100,Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter.,F Wang; K Yang; Z Wang; Y Ma; JS Gutkind; N Hida; G Niu; J Tian,2016,,0.8480013012886047,PMC4753573,
372,8623489,"A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.",C Brattström; G Tydén; J Säwe; G Herlenius; K Claesson; CG Groth,1996,,0.8473345041275024,,
373,15955899,"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.",S Chan; ME Scheulen; S Johnston; K Mross; F Cardoso; C Dittrich; W Eiermann; D Hess; R Morant; V Semiglazov; M Borner; M Salzberg; V Ostapenko; HJ Illiger; D Behringer; N Bardy-Bouxin; J Boni; S Kong; M Cincotta; L Moore,2005,,0.8470288515090942,,
374,15256815,Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs.,L Renders; R Steinbach; T Valerius; HO Schöcklmann; U Kunzendorf,2004,,0.8468793034553528,,
375,20535052,Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.,DJ Moes; RR Press; JW de Fijter; HJ Guchelaar; J den Hartigh,2010,,0.8466914892196655,,
376,33964572,"Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.",G Curigliano; M Martin; K Jhaveri; JT Beck; G Tortora; N Fazio; M Maur; RA Hubner; H Lahner; V Donnet; O Ajipa; Z Li; L Blumenstein; F Andre,2021,Advanced breast cancer; Alpelisib; Everolimus; Exemestane; Hormone receptor–positive; Human epidermal growth factor receptor 2–negative; Maximum tolerated dose; PI3K; Pharmacokinetics; Recommended dose for expansion,0.8458686470985413,,
377,17241922,CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation.,C Jochum; M Beste; E Zellmer; SS Graves; R Storb,2007,,0.8453065752983093,PMC1831459,PK - None | Study Population - None
378,27530708,Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole.,A Petitcollin; R Crochette; C Tron; MC Verdier; C Boglione-Kerrien; C Vigneau; E Bellissant; F Lemaitre,2016,Cytochrome P-450 CYP3A; Drug–drug interaction; Pharmacokinetics; Posaconazole; Sirolimus,0.8441624641418457,,
379,26829601,Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum.,JR Scott; JD Courter; SN Saldaña; BC Widemann; M Fisher; B Weiss; J Perentesis; AA Vinks,2016,,0.8432957530021667,PMC4956590,
380,28829592,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",F Beaufils; N Cmiljanovic; V Cmiljanovic; T Bohnacker; A Melone; R Marone; E Jackson; X Zhang; A Sele; C Borsari; J Mestan; P Hebeisen; P Hillmann; B Giese; M Zvelebil; D Fabbro; RL Williams; D Rageot; MP Wymann,2017,,0.8420929312705994,PMC5656176,
381,30129060,Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.,N Matsubara; Y Naito; K Nakano; Y Fujiwara; H Ikezawa; W Yusa; M Namiki; T Okude; S Takahashi,2018,Japan; clinical trial; everolimus; lenvatinib; renal cell carcinoma,0.8407412767410278,,
382,20975068,Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.,F Andre; M Campone; R O'Regan; C Manlius; C Massacesi; T Sahmoud; P Mukhopadhyay; JC Soria; M Naughton; SA Hurvitz,2010,,0.83885258436203,,
383,12235265,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate.,VJ Wacher; JA Silverman; S Wong; P Tran-Tau; AO Chan; A Chai; XQ Yu; D O'Mahony; Z Ramtoola,2002,,0.8334622383117676,,
384,30635337,Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.,NB Haas; LJ Appleman; M Stein; M Redlinger; M Wilks; X Xu; A Onorati; A Kalavacharla; T Kim; CJ Zhen; S Kadri; JP Segal; PA Gimotty; LE Davis; RK Amaravadi,2019,,0.831587016582489,PMC8915191,
385,8623490,"A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.",EM Johnson; J Zimmerman; K Duderstadt; J Chambers; AL Sorenson; DK Granger; PS Almond; Jp Fryer; JR Leventhal; J Scarola; AJ Matas; DM Canafax,1996,,0.8305600881576538,,
386,30530116,Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling.,RB Verheijen; B Thijssen; F Atrafi; JHM Schellens; H Rosing; N de Vries; JH Beijnen; RHJ Mathijssen; N Steeghs; ADR Huitema,2019,,0.8303343653678894,,
387,26181632,Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus.,Y Lu; N Parker; PJ Kleindl; VA Cross; K Wollak; E Westrick; TW Stinnette; MA Gehrke; K Wang; HK Santhapuram; F You; SJ Hahn; JF Vaughn; PJ Klein; IR Vlahov; PS Low; CP Leamon,2015,,0.8290624618530273,PMC4656201,
388,22878749,A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.,SB Goldberg; JG Supko; JW Neal; A Muzikansky; S Digumarthy; P Fidias; JS Temel; RS Heist; AT Shaw; PO McCarthy; TJ Lynch; S Sharma; JE Settleman; LV Sequist,2012,,0.8289511203765869,PMC3791327,
389,18202410,Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.,MM Mita; AC Mita; QS Chu; EK Rowinsky; GJ Fetterly; M Goldston; A Patnaik; L Mathews; AD Ricart; T Mays; H Knowles; VM Rivera; J Kreisberg; CL Bedrosian; AW Tolcher,2008,,0.8248165845870972,,
390,27259059,"Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients.",KO Zimmerman; H Wu; R Greenberg; JT Guptill; K Hill; UD Patel; L Ku; D Gonzalez; C Hornik; W Jiang; N Zheng; C Melloni; M Cohen-Wolkowiez,2016,,0.8247019052505493,PMC5025355,
391,9585804,Population pharmacokinetics of sirolimus.,GM Ferron; EV Mishina; WJ Jusko; JJ Zimmerman,1998,,0.8232760429382324,,
392,32438078,"Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation.",G Camporese; D Bernardi; E Bernardi; GP Avruscio; F Marchini; L Bonfante; L Furian; F Neri; S Villalta; F Fabris; P Simioni; MT Sartori,2020,Immunosuppressants; Pharmacokinetics; Renal transplantation; Rivaroxaban; Venous thromboembolism,0.8231912851333618,,
393,11267202,Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction.,H Podder; SM Stepkowski; K Napoli; BD Kahan,2001,,0.8230846524238586,,
394,30415142,Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry.,L Wang; Z Tang; M Shi; Q Wang,2019,Consecutive sampling; HPLC-ESI-MS/MS; Nanoformulations; Pharmacokinetics; Rabbit aqueous humor; Sirolimus,0.8223563432693481,,
395,15049798,Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.,AD Schachter; KE Meyers; LD Spaneas; JA Palmer; M Salmanullah; J Baluarte; KL Brayman; WE Harmon,2004,,0.8174867630004883,PMC1350260,
396,23408534,Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.,JG O'Leary; GJ McKenna; GB Klintmalm; GL Davis,2013,,0.8134292364120483,,
397,21389905,CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.,N Picard; K Rouguieg-Malki; N Kamar; L Rostaing; P Marquet,2011,,0.8051217198371887,PMC3324087,
398,18451242,"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.",DA Rizzieri; E Feldman; JF Dipersio; N Gabrail; W Stock; R Strair; VM Rivera; M Albitar; CL Bedrosian; FJ Giles,2008,,0.8010060787200928,,
399,19709321,Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.,C Barau; P Blouin; C Creput; AM Taburet; A Durrbach; V Furlan,2009,,0.79887455701828,,
400,32943547,"Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.",BR Wei; SB Hoover; CJ Peer; JE Dwyer; HA Adissu; P Shankarappa; H Yang; M Lee; TJ Peat; WD Figg; RM Simpson,2020,,0.7983872890472412,PMC8914349,
401,19890249,The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.,N Picard; SW Yee; JB Woillard; Y Lebranchu; Y Le Meur; KM Giacomini; P Marquet,2010,,0.7954897284507751,PMC2884029,
402,20003043,"Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720.",G Weckbecker; C Pally; C Beerli; C Burkhart; G Wieczorek; B Metzler; RE Morris; J Wagner; C Bruns,2010,,0.795355498790741,,
403,19783164,Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.,R Sheshgiri; F Gustafsson; J Sheedy; V Rao; HJ Ross; DH Delgado,2009,,0.7945501208305359,,
404,17504225,A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient.,D Capone; G Palmiero; A Gentile; V Basile; S Federico; M Sabbatini; M Potenza; A Perfetti; M Pieri; G Tarantino,2007,,0.7941562533378601,,
405,18381488,Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.,C Lu; C Berg; SR Prakash; FW Lee; SK Balani,2008,,0.7940801382064819,,
406,22832322,"Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.",RP Wurz; L Liu; K Yang; N Nishimura; Y Bo; LH Pettus; S Caenepeel; DJ Freeman; JD McCarter; EL Mullady; TS Miguel; L Wang; N Zhang; KL Andrews; DA Whittington; J Jiang; R Subramanian; PE Hughes; MH Norman,2012,,0.79237300157547,,
407,31853198,First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.,P Munster; M Mita; A Mahipal; J Nemunaitis; C Massard; T Mikkelsen; C Cruz; L Paz-Ares; M Hidalgo; D Rathkopf; G Blumenschein; DC Smith; B Eichhorst; T Cloughesy; EH Filvaroff; S Li; H Raymon; H de Haan; K Hege; JC Bendell,2019,CC-115; DNA-PK inhibitor; Phase I study; mTOR inhibitor; mTORC1/mTORC2,0.7922629117965698,PMC6916675,
408,27187522,Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.,Q Yu; X Hu; Y Ma; Y Xie; Y Lu; J Qi; L Xiang; F Li; W Wu,2016,Drug delivery; nanoparticles; nanostructured lipid carriers; oral bioavailability; sirolimus,0.7900925874710083,,
409,32150661,Model-Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients.,FP Combes; HJ Einolf; N Coello; T Heimbach; H He; K Grosch,2020,,0.7897822856903076,PMC7180003,PK - None | Study Population - None
410,25361989,Pharmacokinetic interaction involving fenofibrate and everolimus.,O Mir; V Poinsignon; M Arnedos; S Delaloge; A Paci,2015,,0.7887000441551208,,
411,16185865,Rapamycin analogs with reduced systemic exposure.,R Wagner; KW Mollison; L Liu; CL Henry; TA Rosenberg; N Bamaung; N Tu; PE Wiedeman; Y Or; JR Luly; BC Lane; J Trevillyan; YW Chen; T Fey; G Hsieh; K Marsh; M Nuss; PB Jacobson; D Wilcox; RP Carlson; GW Carter; SW Djuric,2005,,0.785979151725769,,
412,32236425,"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.",NJ Ullrich; SP Prabhu; AT Reddy; MJ Fisher; R Packer; S Goldman; NJ Robison; DH Gutmann; DH Viskochil; JC Allen; B Korf; A Cantor; G Cutter; C Thomas; JP Perentesis; T Mizuno; AA Vinks; PE Manley; SN Chi; MW Kieran,2020,NF1; PIK3K/mTOR pathway; RAD001; everolimus; low-grade glioma; neurofibromatosis,0.7856969237327576,PMC7566451,
413,16029064,Sirolimus: the evidence for clinical pharmacokinetic monitoring.,SB Stenton; N Partovi; MH Ensom,2005,,0.7843300700187683,,
414,23455451,Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.,DK Pawaskar; RM Straubinger; GJ Fetterly; BH Hylander; EA Repasky; WW Ma; WJ Jusko,2013,,0.7823118567466736,PMC3755750,
415,15183289,Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.,M Oellerich; VW Armstrong; F Streit; L Weber; B Tönshoff,2004,,0.7816348671913147,,
416,23099651,Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.,EQ Lee; J Kuhn; KR Lamborn; L Abrey; LM DeAngelis; F Lieberman; HI Robins; SM Chang; WK Yung; J Drappatz; MP Mehta; VA Levin; K Aldape; JE Dancey; JJ Wright; MD Prados; TF Cloughesy; MR Gilbert; PY Wen,2012,,0.7810147404670715,PMC3499017,
417,20517177,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.,L Chan; E Hartmann; D Cibrik; M Cooper; LM Shaw,2010,,0.7804813981056213,,
418,17220565,Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation.,E Sato; M Shimomura; S Masuda; I Yano; T Katsura; S Matsumoto; T Okitsu; Y Iwanaga; H Noguchi; H Nagata; Y Yonekawa; K Inui,2006,,0.7801563143730164,,
419,23328074,Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.,DW Coulter; C Walko; J Patel; BM Moats-Staats; A McFadden; SV Smith; WA Khan; AS Bridges; AM Deal; J Oesterheld; IJ Davis; J Blatt,2013,,0.7797590494155884,PMC4005002,
420,16955532,Everolimus drug interactions: application of a classification system for clinical decision making.,JM Kovarik; D Beyer; RL Schmouder,2006,,0.7784494757652283,,
421,11147698,"The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.",VF Quesniaux; K Menninger; A Kunkler; C Vedrine; M Bernhard; R Hedinger; G Kraus; HJ Schuurman,2000,,0.7761643528938293,,
422,19499965,Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient.,EM Billaud; C Antoine; M Berge; I Abboud; S Lefeuvre; M Benammar; D Glotz,2009,,0.7703157663345337,,
423,17096752,Sirolimus pharmacokinetic differences between children and adults.,R Venkataramanan; R Sindhi,2006,,0.7699267864227295,,
424,26036652,Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment.,SS Katiyar; E Muntimadugu; TA Rafeeqi; AJ Domb; W Khan,2016,Breast cancer; P-glycoprotein efflux; PLGA; chemosensitizer; nanoparticles; oral bioavailability; piperine; rapamycin,0.7693179249763489,,
425,16003290,Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment.,M Büchler; Y Lebranchu; M Bénéton; Y Le Meur; AE Heng; PF Westeel; C le Guellec; F Libert; L Hary; P Marquet; G Paintaud,2005,,0.7678818106651306,,
426,24285256,ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.,J Lee; H Huang; Y Chen; X Lu,2014,ABCB1; CYP3A5; polymorphism; renal transplant; sirolimus,0.7655118703842163,,
427,17429314,Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.,N Djebli; N Picard; JP Rérolle; Y Le Meur; P Marquet,2007,,0.7653892636299133,,
428,20512579,Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.,T O'Reilly; HA Lane; JM Wood; C Schnell; A Littlewood-Evans; J Brueggen; PM McSheehy,2011,,0.7653120756149292,,
429,16195616,Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents: lesson from restenosis cases.,M Nakamura; M Wada; H Hara; K Kozuma; Y Otsuka; S Miyazaki,2005,,0.7604354619979858,,
430,22241793,Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R).,WD Paulson; N Kipshidze; K Kipiani; N Beridze; MV DeVita; S Shenoy; SS Iyer,2012,,0.7604057192802429,,
431,17949460,Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.,LA Frassetto; M Browne; A Cheng; AR Wolfe; ME Roland; PG Stock; L Carlson; LZ Benet,2007,,0.7485085725784302,,
432,11034268,"Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry.",PJ Taylor; P Salm; SV Lynch; PI Pillans,2000,,0.7485036253929138,,
433,18360272,"Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection.",T Deuse; JB Velotta; G Hoyt; JA Govaert; V Taylor; E Masuda; E Herlaar; G Park; D Carroll; MP Pelletier; RC Robbins; S Schrepfer,2008,,0.7479439973831177,,
434,33514567,Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression.,PM Kemp Bohan; RC Chick; AE O'Shea; TJ Vreeland; AT Hickerson; JL Cindass; DC Ensley; D Hale; GT Clifton; VY Sohn; IM Thompson; GE Peoples; MA Liss,2021,,0.7438832521438599,,
435,31620236,"Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.",C Borsari; D Rageot; F Beaufils; T Bohnacker; E Keles; I Buslov; A Melone; AM Sele; P Hebeisen; D Fabbro; P Hillmann; MP Wymann,2019,,0.7399904131889343,PMC6792169,PK - Table 5 | Study Population - None
436,23339626,"The pharmacokinetic interaction between mycophenolic acid and cyclosporine revisited: a commentary on ""Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus"".",N Picard,2013,,0.7351495623588562,,
437,26919549,Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.,P Hannun; C Felipe; A Ferreira; T Sandes-Freitas; M Cristelli; W Aguiar; M Franco; E Campos; M Gerbase de Lima; H Tedesco-Silva; J Medina-Pestana,2016,,0.7327715754508972,,
438,31095909,Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease.,C Lee; H Guo; W Klinngam; SR Janga; F Yarber; S Peddi; MC Edman; N Tiwari; S Liu; SG Louie; SF Hamm-Alvarez; JA MacKay,2019,FK506-binding protein; Sjögren’s syndrome; cathepsin S; dacryoadenitis; elastin-like polypeptides; lacrimal gland; non-obese diabetic mouse; rapamycin,0.7326470613479614,PMC6957305,
439,26365907,"A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.",TL Werner; ML Wade; N Agarwal; K Boucher; J Patel; A Luebke; S Sharma,2015,Angiogenesis; Everolimus; JI-101; Ovarian cancer; VEGF,0.7322415113449097,,
440,24637218,CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy.,Y Zhao; T Zhang; S Duan; NM Davies; ML Forrest,2014,Breast cancer; CD44; Hyaluronic acid; Rapamycin,0.7273516654968262,PMC4119834,
441,23956145,Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.,DA Morgenstern; M Marzouki; U Bartels; MS Irwin; GL Sholler; J Gammon; R Yankanah; B Wu; Y Samson; S Baruchel,2014,Phase I; anti-angiogenesis; mTOR; rapamycin; sirolimus; vinblastine,0.7269274592399597,,
442,11510015,Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.,VC McAlister; KM Peltekian; DA Malatjalian; S Colohan; S MacDonald; H Bitter-Suermann; AS MacDonald,2001,,0.726668655872345,,
443,28070711,Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.,J Herskovitz; J Ryman; T Thway; S Lee; L Zhou; N Chirmule; B Meibohm; V Jawa,2017,immune suppression; immunogenicity; preclinical; risk mitigation,0.7228948473930359,,
444,27002938,"A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.",J Mateo; D Olmos; H Dumez; S Poondru; NL Samberg; S Barr; JM Van Tornout; F Jie; S Sandhu; DS Tan; V Moreno; PM LoRusso; SB Kaye; P Schöffski,2016,,0.7227244973182678,PMC4984800,
445,30663344,HPLC-MS/MS-based analysis of everolimus in rabbit aqueous humor: pharmacokinetics of in situ gel eye drops of suspension.,Z Tang; L Wang; Z Xia; M Shi; Q Wang; Z Zhan,2019,HPLC–MS/MS; aqueous humor; everolimus; pharmacokinetics,0.7220468521118164,,
446,1585399,Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography.,RW Yatscoff; C Faraci; P Bolingbroke,1992,,0.7195921540260315,,
447,18332469,Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.,J Tabernero; F Rojo; E Calvo; H Burris; I Judson; K Hazell; E Martinelli; S Ramon y Cajal; S Jones; L Vidal; N Shand; T Macarulla; FJ Ramos; S Dimitrijevic; U Zoellner; P Tang; M Stumm; HA Lane; D Lebwohl; J Baselga,2008,,0.7185867428779602,,
448,32975132,Designing orodispersible films containing everolimus for enhanced compliance and bioavailability.,Y Ma; R Guan; S Gao; W Song; Y Liu; Y Yang; H Liu,2020,Acacia gum; everolimus; oral bioavailability; orodispersible film; patient compliance; stability,0.7088708281517029,,
449,26062846,Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.,B Huang; WD Abraham; Y Zheng; SC Bustamante López; SS Luo; DJ Irvine,2015,,0.7085944414138794,PMC4687972,
450,25165011,"A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma.",X Ding; F Li; J McKnight; C Schmidt; K Strooisma; H Shimizu; K Faber; JA Ware; B Dean,2014,Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR); GDC-0980 (Apitolisib); Human plasma; LC–MS/MS; Solid supported liquid extraction,0.7069839239120483,,
451,34310349,Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.,M Amin; F Gao; G Terrero; J Picus; A Wang-Gillam; R Suresh; C Ma; B Tan; M Baggstrom; MJ Naughton; L Trull; S Belanger; PM Fracasso; AC Lockhart,2021,,0.7053436040878296,,
452,25673697,"A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.",TK Owonikoko; SS Ramalingam; DL Miller; SD Force; GL Sica; J Mendel; Z Chen; A Rogatko; M Tighiouart; RD Harvey; S Kim; NF Saba; A Pickens; M Behera; RW Fu; MR Rossi; WF Auffermann; WE Torres; R Bechara; X Deng; SY Sun; H Fu; AA Gal; FR Khuri,2015,,0.7051956057548523,PMC4401630,
453,30259313,Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane.,AECAB Willemsen; LF de Geus-Oei; M de Boer; J Tol; Y Kamm; PC de Jong; MA Jonker; AH Vos; W Grootjans; JWB de Groot; SF Mulder; EHJG Aarntzen; WR Gerritsen; CML van Herpen; NP van Erp,2018,,0.7035148739814758,,
454,31527867,A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.,E Wolin; A Mita; A Mahipal; T Meyer; J Bendell; J Nemunaitis; PN Munster; L Paz-Ares; EH Filvaroff; S Li; K Hege; H de Haan; M Mita,2019,,0.6979137063026428,PMC6748410,PK - Table 3 | Study Population - Table 1
455,21332118,Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.,ND D'Angelo; TS Kim; K Andrews; SK Booker; S Caenepeel; K Chen; D D'Amico; D Freeman; J Jiang; L Liu; JD McCarter; T San Miguel; EL Mullady; M Schrag; R Subramanian; J Tang; RC Wahl; L Wang; DA Whittington; T Wu; N Xi; Y Xu; P Yakowec; K Yang; LP Zalameda; N Zhang; P Hughes; MH Norman,2011,,0.6961095929145813,,
456,33808416,Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.,AN Sabo; S Jannier; G Becker; JM Lessinger; N Entz-Werlé; V Kemmel,2021,Monolix® software; pediatric oncology; pharmacokinetic population modeling; pharmacokinetics; sirolimus; therapeutic drug monitoring,0.6928524374961853,PMC8067051,PK - Table 3 | Study Population - Table 2
457,21981714,"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.",DP Sutherlin; L Bao; M Berry; G Castanedo; I Chuckowree; J Dotson; A Folks; L Friedman; R Goldsmith; J Gunzner; T Heffron; J Lesnick; C Lewis; S Mathieu; J Murray; J Nonomiya; J Pang; N Pegg; WW Prior; L Rouge; L Salphati; D Sampath; Q Tian; V Tsui; NC Wan; S Wang; B Wei; C Wiesmann; P Wu; BY Zhu; A Olivero,2011,,0.6922533512115479,,
458,24923538,Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.,C Machka; S Lange; J Werner; R Wacke; D Killian; A Knueppel; G Knuebel; H Vogel; I Lindner; C Roolf; H Murua Escobar; C Junghanss,2014,Allogeneic hematopoietic stem cell transplantation; Dogs; Everolimus; Nonmyeloablative conditioning; Pharmacokinetics,0.6865377426147461,,
459,23294893,Drug-containing gelatin treats as an alternative to gavage for long-term oral administration in rhesus monkeys (Macaca mulatta).,S Zhang; B Ye; L Zeng; Y Chen; S He; C Wang; X Li; J Zhao; M Shi; L Wang; H Li; J Cheng; W Wang; Y Lu,2012,,0.6864833831787109,PMC3508191,
460,24628014,"The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.",KE Schoeppler; CL Aquilante; TH Kiser; DN Fish; MR Zamora,2014,cystic fibrosis; diltiazem; everolimus; lung transplantation; pharmacogenetics,0.6855599880218506,,
461,22686837,A study about drug combination therapy of Schisandra sphenanthera extract and Rapamycin in healthy subjects.,R Li; W Guo; Z Fu; G Ding; Z Wang; H Fu,2012,,0.684329092502594,,
462,26325438,"Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.",SK Khaled; JM Palmer; J Herzog; T Stiller; NC Tsai; D Senitzer; X Liu; SH Thomas; S Shayani; J Weitzel; SJ Forman; R Nakamura,2016,"Drug absorption, distribution, metabolism, and excretion (ADME); Immunosuppressant; Pharmacogenetics",0.6836122870445251,PMC4716887,
463,21835932,"Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.",X Wang; Y Zhan; L Zhao; J Alvarez; I Chaudhary; BB Zhou; RT Abraham; GZ Feuerstein,2011,,0.6815189719200134,,
464,23579358,"Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.",WE Eberhardt; P Mitchell; JH Schiller; MP Brown; M Thomas; G Mills; V Jehl; SR Urva; JJ De Leo; S Gogov; V Papadimitrakopoulou,2014,,0.6813012957572937,,
465,31325105,Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.,AECAB Willemsen; J Tol; NP van Erp; MA Jonker; M de Boer; B Meek; PC de Jong; C van Moorsel; WR Gerritsen; JC Grutters; CML van Herpen,2019,,0.678998589515686,PMC6684805,
466,23199076,"Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.",MF Koehler; P Bergeron; E Blackwood; KK Bowman; YH Chen; G Deshmukh; X Ding; J Epler; K Lau; L Lee; L Liu; C Ly; S Malek; J Nonomiya; J Oeh; DF Ortwine; D Sampath; S Sideris; L Trinh; T Truong; J Wu; Z Pei; JP Lyssikatos,2012,,0.6750470995903015,,
467,24908540,A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.,T Powles; SJ Foreshew; J Shamash; N Sarwar; S Crabb; A Sahdev; J Nixon; L Lim; A Pungaliya; A Foreshaw; R Davies; M Greenwood; P Wilson; S Pacey; M Galazi; R Jones; S Chowdhury,2014,Combination; Dovitinib; Everolimus; FGF; Renal cancer; VEFG; mTOR,0.6744459867477417,,
468,19491334,Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.,D Cattaneo; M Cortinovis; S Baldelli; E Gotti; G Remuzzi; N Perico,2009,,0.6724650859832764,,
469,34224367,Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.,MA Karajannis; A Mauguen; E Maloku; Q Xu; EM Dunbar; SR Plotkin; A Yaffee; S Wang; JT Roland; C Sen; DG Placantonakis; JG Golfinos; JC Allen; NA Vitanza; LA Chiriboga; RJ Schneider; J Deng; TA Neubert; JD Goldberg; D Zagzag; FG Giancotti; JO Blakeley,2021,,0.6671620011329651,PMC8419097,
470,17201457,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.,CE Staatz; SE Tett,2007,,0.6659905910491943,,
471,24013904,Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.,SJ Lee; J Lee; J Lee; SH Park; JO Park; YS Park; HY Lim; KM Kim; IG Do; SH Jung; DS Yim; WK Kang,2013,,0.6655037999153137,,
472,29159710,Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.,H Colom; F Andreu; T van Gelder; DA Hesselink; BCM de Winter; O Bestard; J Torras; JM Cruzado; JM Grinyó; N Lloberas,2018,,0.665460467338562,,
473,18842108,A rapid liquid chromatography-tandem mass spectrometry analysis of whole blood sirolimus using turbulent flow technology for online extraction.,S Wang; A Miller,2008,,0.663872480392456,,
474,19662626,Liquid chromatography-tandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents.,G Rajender; NG Narayanan,2010,,0.6592699289321899,,
475,18367972,Pharmacokinetics of mycophenolate mofetil and sirolimus in children.,G Filler; J Bendrick-Peart; U Christians,2008,,0.6549548506736755,,
476,19584690,Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.,HB Lehmkuhl; J Arizon; M Viganò; L Almenar; G Gerosa; M Maccherini; S Varnous; F Musumeci; JM Hexham; KC Mange; U Livi; ,2009,,0.6541650295257568,,
477,24727322,"P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.",SC Tang; RW Sparidans; KL Cheung; T Fukami; S Durmus; E Wagenaar; T Yokoi; BJ van Vlijmen; JH Beijnen; AH Schinkel,2014,,0.6505066156387329,,
478,21322566,"Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.",Q Liu; J Wang; SA Kang; CC Thoreen; W Hur; T Ahmed; DM Sabatini; NS Gray,2011,,0.6500575542449951,PMC3090687,
479,23305536,Enhanced solubility and oral absorption of sirolimus using D-α-tocopheryl polyethylene glycol succinate micelles.,MS Kim; JS Kim; WK Cho; SJ Hwang,2013,,0.6479368805885315,,
480,20155737,Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment.,JC Lukas; R Calvo; A Zografidis; I Ortega; E Suárez,2010,,0.6447438597679138,,
481,31376625,Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation.,T Hiramitsu; T Tomosugi; K Futamura; M Okada; N Goto; T Ichimori; S Narumi; Y Watarai,2019,Cyclosporine A; Dose administration; Everolimus; Living donor kidney transplantation; Tacrolimus,0.6446499824523926,,
482,31408605,Molecular Targeting of Immunosuppressants Using a Bifunctional Elastin-Like Polypeptide.,Y Ju; H Guo; F Yarber; MC Edman; S Peddi; SR Janga; JA MacKay; SF Hamm-Alvarez,2019,,0.6378941535949707,PMC6980866,
483,9097913,Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection.,SM Stepkowski; L Tian; KL Napoli; R Ghobrial; ME Wang; TC Chou; BD Kahan,1997,,0.6368626952171326,PMC1904622,
484,14620947,"Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.",L Renders; D Czock; H Schöcklmann; U Kunzendorf,2003,,0.6329609155654907,,
485,10770413,Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.,BD Kahan; KL Napoli; PA Kelly; J Podbielski; I Hussein; DL Urbauer; SH Katz; CT Van Buren,2000,,0.6326906085014343,,
486,23018468,Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.,TK Bergmann; KA Barraclough; KJ Lee; CE Staatz,2012,,0.6303287744522095,,
487,23913602,Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents.,SK Yazdani; A Sheehy; M Nakano; G Nakazawa; M Vorpahl; F Otsuka; RS Donn; LE Perkins; CA Simonton; FD Kolodgie; R Virmani,2013,,0.6289114952087402,,
488,29668485,Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.,A Raimondi; F Colombo; G Pintarelli; C Morosi; SL Renne; AM Frezza; M Saponara; AP Dei Tos; A Mazzocchi; S Provenzano; PG Casali; S Stacchiotti,2018,,0.628128707408905,,
489,23953523,"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients.",WO Bechstein; L Paczek; L Wramner; JP Squifflet; AJ Zygmunt; ,2013,,0.621688961982727,,
490,22067664,Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.,SE Krown; D Roy; JY Lee; BJ Dezube; EG Reid; R Venkataramanan; K Han; E Cesarman; DP Dittmer,2012,,0.6161113381385803,PMC3302934,
491,28076966,"EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.",M El-Madani; O Colomban; M Tod; D Maillet; J Peron; C Rodriguez-Lafrasse; OA Badary; PJ Valette; T Lefort; P Cassier; SM El-Shenawy; E El-Demerdash; J Hommel-Fontaine; J Guitton; MC Gagnieu; BM Ibrahim; C Barrois; G Freyer; B You,2017,Phase I; administration and dosage; adverse events; angiogenesis inhibitors; everolimus; maximum tolerated dose; modeling; pharmacokinetics; solid tumor; sorafenib; targeted therapy,0.6157126426696777,,
492,26428893,In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system.,JF Granada; A Tellez; WR Baumbach; B Bingham; YF Keng; J Wessler; G Conditt; J McGregor; G Stone; GL Kaluza; MB Leon,2016,,0.6156014800071716,,
493,8004232,Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations.,KL Napoli; BD Kahan,1994,,0.6151479482650757,,
494,24521776,More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.,I Robertsen; A Asberg; T Granseth; NT Vethe; F Akhlaghi; M Ghareeb; E Molden; M Reier-Nilsen; H Holdaas; K Midtvedt,2014,,0.6141878962516785,PMC4127422,
495,19458944,The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.,F Gustafsson; D Barth; DH Delgado; M Nsouli; J Sheedy; HJ Ross,2009,,0.6116631627082825,,
496,12742493,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty.,H Tedesco Silva; CR Felipe; PG Machado; R Garcia; S Motegi; BH Hosaka; NM Hanzawa; SI Park; D Casarini; VC Lima; M Franco; JO Medina-Pestana,2003,,0.6101864576339722,,
497,28169165,Synthesis and evaluation of an injectable everolimus prodrug.,H Wang; X Zheng; Z Cai; O Yu; S Zheng; T Zhu,2017,Everolimus; Glutathione; Injectable; Long-acting; Prodrug; mTOR,0.6100703477859497,,
498,26178426,Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.,DE Rathkopf; SM Larson; A Anand; MJ Morris; SF Slovin; DR Shaffer; G Heller; B Carver; N Rosen; HI Scher,2015,mammalian target of rapamycin (mTOR); pharmacokinetics; prostatic neoplasms; quinazolines (gefitinib); sirolimus derivatives (everolimus); target of rapamycin (TOR) serine-threonine kinases,0.6083893179893494,PMC4618268,
499,16995869,A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.,N Picard; A Prémaud; A Rousseau; Y Le Meur; P Marquet,2006,,0.6083489060401917,PMC1885150,
500,23773100,Tivozanib for the treatment of metastatic renal cancer.,HH Wong; T Eisen,2013,,0.6074692010879517,,
501,16467100,Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.,DA Reardon; JA Quinn; JJ Vredenburgh; S Gururangan; AH Friedman; A Desjardins; S Sathornsumetee; JE Herndon; JM Dowell; RE McLendon; JM Provenzale; JH Sampson; RP Smith; AJ Swaisland; JS Ochs; P Lyons; S Tourt-Uhlig; DD Bigner; HS Friedman; JN Rich,2006,,0.6074671745300293,,
502,16386527,Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study.,J Pascual; R Marcén; OE Orea; M Navarro; MC Alarcón; J Ocaña; JJ Villafruela; FJ Burgos; J Ortuño,2005,,0.6072086691856384,,
503,16860172,A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.,AO Dösch; P Ehlermann; A Koch; A Remppis; HA Katus; TJ Dengler,2006,,0.607049286365509,,
504,21704741,Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy.,P Parhi; C Mohanty; SK Sahoo,2011,,0.6043504476547241,,
505,32595509,Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex.,DD Wang; X Chen; H Xu; ZP Li,2020,children; initial dosage; recommendation; sirolimus; tuberous sclerosis complex,0.6011577844619751,PMC7300220,PK - Table 3 | Study Population - Table 1
506,19715848,De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.,M Crespo; M Mir; M Marin; S Hurtado; C Estadella; X Gurí; O Rap; R Moral; JM Puig; J Lloveras,2009,,0.6007145047187805,,
507,27103123,Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.,J Li; H Kluger; L Devine; JJ Lee; WK Kelly; L Rink; MW Saif,2016,Phase 1; Sirolimus; Sunitinib,0.5998607277870178,,
508,18547473,Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients.,D Capone; A Gentile; G Polichetti; S Federico; M Sabbatini; A Acampora; V Basile; M Pieri; G Tarantino,2008,,0.5964771509170532,,
509,20442358,Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix.,JF Granada; S Inami; MS Aboodi; A Tellez; K Milewski; D Wallace-Bradley; S Parker; S Rowland; G Nakazawa; M Vorpahl; FD Kolodgie; GL Kaluza; MB Leon; R Virmani,2010,,0.5918310284614563,,
510,20484171,Significant sirolimus and dronedarone interaction in a kidney transplant recipient.,EM Tichy; AJ Medwid; EA Mills; RN Formica; S Kulkarni,2010,,0.5901584625244141,,
511,31863795,Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis.,HY Ang; GM Xiong; SY Chaw; JL Phua; JCK Ng; PEH Wong; S Venkatraman; TT Chong; Y Huang,2020,Drug delivery systems; Nanocarriers; Peripheral artery disease; Sirolimus; Sustained release; Vascular restenosis,0.5875660181045532,,
512,24861504,"Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.",F Shihab; U Christians; L Smith; JR Wellen; B Kaplan,2014,Calcineurin inhibitors; Pharmacokinetics; Renal transplantation; Tacrolimus; Therapeutic drug monitoring; mTOR inhibitors,0.5844706296920776,,
513,10871329,Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine.,N Serkova; B Hausen; GJ Berry; W Jacobsen; LZ Benet; RE Morris; U Christians,2000,,0.584021270275116,,
514,24569835,Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.,E Blanco; T Sangai; S Wu; A Hsiao; GU Ruiz-Esparza; CA Gonzalez-Delgado; FE Cara; S Granados-Principal; KW Evans; A Akcakanat; Y Wang; KA Do; F Meric-Bernstam; M Ferrari,2014,,0.5817800164222717,PMC4088997,
515,16778729,Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants.,LS Ting; E Villeneuve; MH Ensom,2006,,0.5782959461212158,,
516,22844126,Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.,Y Sun; S Rha; SH Lee; J Guo; T Ueda; S Qin; S Naito; M Cincotta; K Tokushige; H Akaza,2012,,0.5770030617713928,,
517,33356170,Intralacrimal Sustained Delivery of Rapamycin Shows Therapeutic Effects without Systemic Toxicity in a Mouse Model of Autoimmune Dacryoadenitis Characteristic of Sjögren's Syndrome.,Y Ju; MC Edman; H Guo; SR Janga; S Peddi; SG Louie; JA Junge; JA MacKay; SF Hamm-Alvarez,2021,,0.5765882134437561,PMC8015671,
518,26951309,"Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.",T Powles; MR Lackner; S Oudard; B Escudier; C Ralph; JE Brown; RE Hawkins; D Castellano; BI Rini; MD Staehler; A Ravaud; W Lin; B O'Keeffe; Y Wang; S Lu; JM Spoerke; LY Huw; M Byrtek; R Zhu; JA Ware; RJ Motzer,2016,,0.575096845626831,PMC5569691,
519,23436212,Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.,F Lin; L Buil; D Sherris; JH Beijnen; O van Tellingen,2013,ABCB1; ABCG2; Palomid 529; blood-brain barrier; mTOR inhibitor,0.5736545324325562,,
520,18757332,"Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.",A Jimeno; MA Rudek; P Kulesza; WW Ma; J Wheelhouse; A Howard; Y Khan; M Zhao; H Jacene; WA Messersmith; D Laheru; RC Donehower; E Garrett-Mayer; SD Baker; M Hidalgo,2008,,0.5656828880310059,PMC2654371,
521,17705579,T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy.,M Brunet; JM Campistol; F Diekmann; D Guillen; O Millán,2007,,0.5648618936538696,,
522,9840435,Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry.,PJ Taylor; AG Johnson,1998,,0.5639244914054871,,
523,23455452,Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.,DK Pawaskar; RM Straubinger; GJ Fetterly; BH Hylander; EA Repasky; WW Ma; WJ Jusko,2013,,0.5606333017349243,PMC3752659,
524,18381489,Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.,C Lu; P Hatsis; C Berg; FW Lee; SK Balani,2008,,0.5522454380989075,,
525,20920162,Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.,Q Chang; MS Chapman; JN Miner; DW Hedley,2010,,0.5512520670890808,PMC2955043,
526,25944843,A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An Experimental Study Utilizing Porcine Model of In-Stent Restenosis.,B Orlik; PP Buszman; A Krauze; P Gąsior; P Desperak; J Pająk; J Kasperczyk; A Janas; M Jelonek; G Handzlik-Orlik; PE Buszman; K Milewski,2016,NMR spectroscopy; biodegradable polymer; coronary stents; porcine model; sirolimus-eluting stent,0.5484573245048523,,
527,31752553,Preparation and study of two kinds of ophthalmic nano-preparations of everolimus.,Z Tang; L Yin; Y Zhang; W Yu; Q Wang; Z Zhan,2019,Everolimus; micelles; nanosuspension; pharmacokinetics,0.5457029938697815,PMC6882435,PK - Table 4 | Study Population - None
528,25358900,Pharmacokinetics of therapeutic Tregs.,Q Tang,2014,,0.5427129864692688,,
529,21839257,Factors that affect concentrations of cyclosporine during the induction period of kidney transplantation: multivariate analysis.,P Troncoso; AM Ortiz; S Vilches,2011,,0.5423572659492493,,
530,33753454,"Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.",AK LeBlanc; CN Mazcko; A Cherukuri; EP Berger; WC Kisseberth; ME Brown; SE Lana; K Weishaar; BK Flesner; JN Bryan; DM Vail; JH Burton; JL Willcox; AJ Mutsaers; JP Woods; NC Northrup; C Saba; KM Curran; H Leeper; H Wilson-Robles; BG Wustefeld-Janssens; S Lindley; AN Smith; N Dervisis; S Klahn; ML Higginbotham; RM Wouda; E Krick; JA Mahoney; CA London; LG Barber; CE Balkman; AL McCleary-Wheeler; SE Suter; O Martin; A Borgatti; K Burgess; MO Childress; JL Fidel; SD Allstadt; DL Gustafson; LE Selmic; C Khanna; TM Fan,2021,,0.5397779941558838,PMC8172450,
531,20797855,PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.,AM Venkatesan; Z Chen; O dos Santos; C Dehnhardt; ED Santos; S Ayral-Kaloustian; R Mallon; I Hollander; L Feldberg; J Lucas; K Yu; I Chaudhary; TS Mansour,2010,,0.5395352244377136,,
532,33277457,Sirolimus Dose Requirement in Kidney Transplant Recipients in Iran.,G Ghasemi; S Shahidi; Z Farajzadegan; S Shahidi; M Mohammadi,2020,,0.539426326751709,,
533,27494885,Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.,E Gaudio; C Tarantelli; M Ponzoni; E Odore; K Rezai; E Bernasconi; L Cascione; A Rinaldi; A Stathis; E Riveiro; E Cvitkovic; E Zucca; F Bertoni,2016,BET inhibitor; everolimus; ibrutinib; rituximab; vorinostat,0.5372170209884644,PMC5295419,
534,26364551,A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.,T Powles; M Wheater; O Din; T Geldart; E Boleti; A Stockdale; S Sundar; A Robinson; I Ahmed; A Wimalasingham; W Burke; SJ Sarker; S Hussain; C Ralph,2016,Renal cancer; Survival; TORC2; mTOR,0.534974992275238,,
535,15575918,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.,RC Starling; JM Hare; P Hauptman; KR McCurry; HW Mayer; JM Kovarik; H Schmidli,2004,,0.5334439277648926,,
536,10194039,Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine.,B Hausen; K Boeke; GJ Berry; IT Segarra; U Christians; RE Morris,1999,,0.5288650989532471,,
537,30323313,Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients.,S Si; Z Wang; H Yang; Z Han; J Tao; H Chen; K Wang; M Guo; R Tan; JF Wei; M Gu,2019,,0.5275402665138245,,
538,17722509,Nanomedicines in renal transplant rejection--focus on sirolimus.,LJ Shen; FL Wu,2007,,0.52692711353302,PMC2673820,PK - None | Study Population - None
539,22797386,Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.,AS Strimpakos; KN Syrigos; MW Saif,2012,,0.5244149565696716,,
540,30830337,Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.,D Lesche; V Sigurdardottir; AB Leichtle; CT Nakas; U Christians; L Englberger; M Fiedler; CR Largiadèr; P Mohacsi; J Sistonen,2017,Dose requirement; Everolimus metabolism; Heart transplantation; Pharmacometabolomics,0.5226112604141235,,
541,30906563,Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study.,S Takasaki; H Yamaguchi; Y Kawasaki; M Kikuchi; M Tanaka; A Ito; N Mano,2019,Everolimus; Pharmacokinetics; Renal cell carcinoma; Therapeutic drug monitoring; mTOR,0.5218610167503357,PMC6413453,
542,28109945,Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.,J Zhang; X Lv; X Ma; Y Hu,2017,Cancer; Inhibitor; PI3K; mTOR,0.5178475379943848,,
543,11523724,Clinical pharmacokinetics of sirolimus.,K Mahalati; BD Kahan,2001,,0.5172237157821655,,
544,34819851,Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma.,"Chen, Xiao, Wang, Dongdong, Wang, Guangfei, Huang, Yidie, Yu, Xin, Lu, Jinmiao, Zhai, Xiaowen, Xu, Hong, Li, Zhiping",2021,"initial dose regimen, lymphangioma, optimization, pediatric, sirolimus",0.8829255700111389,PMC8606893,PK - TABLE 2 | Study Population - TABLE 1
545,34957601,Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.,"Harbers, Veroniek E M, van der Salm, Nathalie, Pegge, Sjoert A H, van der Vleuten, Carine J M, Verhoeven, Bas H, Vrancken, Sabine L A G, Schultze Kool, Leo J, Fuijkschot, Joris, Te Loo, D Maroeska M W M",2022,"Kasabach-Merritt phenomenon, kaposiform haemangioendothelioma, sirolimus, vascular tumour",0.5911946892738342,PMC9303919,PK - None | Study Population - TABLE 1
546,35234223,A gold-based immunochromatographic strip for the detection of sirolimus in human whole blood.,"Jiang, Xiaoqian, Xu, Xinxin, Zeng, Lu, Song, Shanshan, Xu, Liguang, Kuang, Hua, Liu, Liqiang, Xu, Chuanlai",2022,,0.6174682378768921,,
547,35631669,"Targeting Peptide, Fluorescent Reagent Modified Magnetic Liposomes Coated with Rapamycin Target Early Atherosclerotic Plaque and Therapy.","Huang, Chen, Huang, Wentao, Zhang, Lifen, Zhang, Chunyu, Zhou, Chengqian, Wei, Wei, Li, Yongsheng, Zhou, Quan, Chen, Wenli, Tang, Yukuan",2022,"MRI, Rap/Fe3O4@VHP-Lipo, VCAM-1, bimodal imaging, early atherosclerosis, rapamycin",0.7826897501945496,PMC9146689,
548,35774599,UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma.,"Li, Qingqing, Liu, Ya-Nan, Wang, Jing, Hu, Yingying, Hu, Jinyu, Xu, Ren-Ai, Shao, Liu, Chen, Lianguo",2022,"UPLC-MS/MS technology, pharmacokinetic analysis, quantitative methodology, rat plasma, voxtalisib",0.978543221950531,PMC9237521,PK - TABLE 4 | Study Population - None
549,35846221,"Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.","Ribrag, Vincent, Chavez, Julio C, Boccomini, Carola, Kaplan, Jason, Chandler, Jason C, Santoro, Armando, Corradini, Paolo, Flinn, Ian W, Advani, Ranjana, Cassier, Philippe A, Sangha, Randeep, Kenkre, Vaishalee P, Isufi, Iris, Uttamsingh, Shailaja, Hagner, Patrick R, Gandhi, Anita K, Shen, Frank, Michelliza, Sophie, Haeske, Harald, Hege, Kristen, Pourdehnad, Michael, Kuruvilla, John",2022,"new drug development, non-Hodgkin lymphoma, phase 1 clinical trials",0.6020861864089966,PMC9176062,PK - None | Study Population - TABLE 1
550,35863592,Rat synovial tissue and blood rapamycin pharmacokinetics after intra-articular injection of free solution or nanoparticles vs free rapamycin intravenous shot.,"Pape, Elise, Pinzano, Astrid, Henrionnet, Christel, Scala-Bertola, Julien, Gillet, Pierre, Gambier, Nicolas",2022,,0.6949563026428223,,
551,35935636,Five-year comparative study of thin-strut rapamycin-eluting bioabsorbable scaffold with metallic drug-eluting stent in porcine coronary artery.,"Liu, Yaokun, Zheng, Bo, Zhang, Bin, Ndondo-Lay, Robert, Nie, Fangfang, Tang, Naijie, Miao, Yongsheng, Li, Jianping, Huo, Yong",2022,"bioabsorbable scaffold, coronary disease, histopathology, optical coherence tomography, swine model",0.7325330972671509,PMC9355424,PK - None | Study Population - None
552,36004935,Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics.,"Itohara, Kotaro, Yano, Ikuko, Nakagawa, Shunsaku, Sugimoto, Mitsuhiro, Hirai, Machiko, Yonezawa, Atsushi, Imai, Satoshi, Nakagawa, Takayuki, Hira, Daiki, Ito, Takashi, Hata, Koichiro, Hatano, Etsuro, Terada, Tomohiro, Matsubara, Kazuo",2022,,0.8346235156059265,PMC9652441,PK - TABLE 2 | Study Population - TABLE 1
553,36188573,Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.,"Chen, Xiao, Wang, Jinglin, Lan, Jianger, Ge, Xilin, Xu, Hong, Zhang, Yu, Li, Zhiping",2022,"PIK3CD mutation, immunodeficiency disease, initial dosages recommendation, pediatric patients, sirolimus",0.7836294770240784,PMC9515533,PK - TABLE 2 | Study Population - TABLE 1
554,36233042,Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients.,"Yagishita, Hironobu, Kagaya, Hideaki, Saito, Mitsuru, Numakura, Kazuyuki, Yamamoto, Ryohei, Sagehashi, Ryuichiro, Habuchi, Tomonori, Satoh, Shigeru, Miura, Masatomo",2022,"P-glycoprotein, everolimus, polymorphism, pregnane X-receptor",0.6774430274963379,PMC9570057,PK - Table 2 | Study Population - Table 1
555,36416673,Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects.,"Zha, Jiuhong, Jiang, Qi, Yao, Betty B, Cohen, Daniel E, Carter, David C, Menon, Rajeev M",2022,"CYP3A inhibitor, dasabuvir, everolimus, hepatitis C, ombitasvir, paritaprevir, ritonavir, sirolimus",0.5056039690971375,PMC9683076,"PK - TABLE 1, TABLE 2 | Study Population - None"
556,36678783,"Evaluation of pH-Sensitive Polymeric Micelles Using Citraconic Amide Bonds for the Co-Delivery of Paclitaxel, Etoposide, and Rapamycin.","Jo, Min Jeong, Shin, Hee Ji, Yoon, Moon Sup, Kim, Seo Yeon, Jin, Chae Eun, Park, Chun-Woong, Kim, Jin-Seok, Shin, Dae Hwan",2023,"combination index, combination therapy, gastric cancer, pH-sensitive polymeric micelles, pharmacokinetics",0.8574634790420532,PMC9866473,PK - Table 4 | Study Population - None
557,36830793,Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders.,"Passannante, Rossana, Gomez-Vallejo, Vanessa, Sagartzazu-Aizpurua, Maialen, Vignau Arsuaga, Laura, Marco-Moreno, Pablo, Aldanondo, Garazi, Vallejo-Illarramendi, Ainara, Aguiar, Pablo, Cossio, Unai, Martin, Abraham, Bergare, Jonas, Kingston, Lee, Elmore, Charles S, Morcillo, Miguel Angel, Ferron, Pablo, Aizpurua, Jesus M, Llop, Jordi",2023,"PET, pharmacokinetics, radiolabelling",0.9304044246673584,PMC9953224,"PK - Table 1, Table 2 | Study Population - None"
558,37493814,Antitumor activity of 5-fluorouracil polymeric nanogel synthesized by gamma radiation on a rat model of colon carcinoma: a proposed mechanism.,"Abo-Zaid, Omayma A R, Moawed, Fatma S M, Barakat, Wael E M, Ghobashy, Mohamed Mohamady, Ahmed, Esraa S A",2023,"5-fluorouracil nanogel, AKT, Autophagy, Colon cancer, NF-kappabeta, PI3K, TLR2, mTOR",0.6167749762535095,PMC10371941,PK - None | Study Population - None
559,37579189,Pharmacokinetics of Sirolimus Eye Drops Following Topical Ocular Administration in Rabbits.,"Lin, Junli, Lu, Ziqi, Wang, Yandong, Zhang, Jiawei, Guo, Jianmin, Huang, Yuankeng, Lin, Baoqin, Yang, Wei",2023,"dry eye disease, eye drops, pharmacokinetics, sirolimus",0.6820060014724731,,
560,37868642,"Microsponge-derived mini tablets loaded with immunosuppressive agents: Pharmacokinetic investigation in human volunteers, cell viability and IVIVC correlation.","Mehmood, Yasir, Shahid, Hira, Abbas, Muhammad, Farooq, Umar, Ali, Shaukat, Kazi, Mohsin",2023,"Bioavailability, IVIVC, Sirolimus, Solid dispersions, Solubility",0.9709057211875916,PMC10585343,"PK - Table 4, Table 5 | Study Population - None"
561,38074125,Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia.,"Park, Jinha, Kim, Se Hee, Hahn, Jongsung, Kang, Hoon-Chul, Lee, Sang-Guk, Kim, Heung Dong, Chang, Min Jung",2023,"epilepsy, everolimus, focal cortical dysplasia, non-linear mixed-effect modeling, population pharmacokinetics",0.9672607183456421,PMC10704167,PK - TABLE 2 | Study Population - TABLE 1
562,38500383,"Dosing-time, feeding, and sex-dependent variations of everolimus pharmacokinetics in mice.","Ozturk Civelek, Dilek, Ozturk Seyhan, Narin, Akyel, Yasemin Kubra, Gazioglu, Isil, Pala Kara, Zeliha, Orman, Mehmet N, Okyar, Alper",2024,"chronomodulated chemotherapy, chronopharmacokinetics, everolimus, fed/fasted, sex difference",0.9877815246582031,,
563,38547661,Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy.,"Sakaue, Tomoyuki, Yamamoto, Kazuhiro, Itohara, Kotaro, Kitahiro, Yumi, Endo, Takahito, Yokoyama, Naoki, Ishimura, Takeshi, Omura, Tomohiro, Yano, Ikuko",2024,"Everolimus, Population pharmacokinetics, Renal transplantation, Tacrolimus, Therapeutic drug monitoring",0.604813814163208,,
564,38960206,Model-Informed individualized dosage regimen of sirolimus in pediatric patients with intractable lymphatic malformations.,"Liu, Bo, Zhang, Xuexi, Zhao, Yiming, Xu, Xiaolin, Wang, Shengcai, Wang, Xiaoling, Cheng, Xiaoling",2024,"Individualized medication, Intractable lymphatic malformation, Pediatrics, Population pharmacokinetic model, Sirolimus",0.5944049954414368,,
565,38984822,"Comprehensive Assessment of Drug Kinetics, Neurotoxicity, and Safety of Sirolimus-Eluting Intracranial Stents in Canine Basilar Artery.","Sun, Xuan, Wu, Xiaojin, Yang, Ming, Deng, Yiming, Jia, Baixue, Zhang, Xuelei, Zhang, Min, Pi, Chaoqiong, Bureau, Christophe, Caligiuri, Giuseppina, Miao, Zhongrong",2024,,0.7477536201477051,,
566,39121325,Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway.,"Kirkeby, Kjersti, Cockerell, Ine, Christensen, Jakob, Hoei-Hansen, Christina Engel, Holst, Lotte, Fredriksen, Mikkel G, Lund, Caroline, Johannessen Landmark, Cecilie",2024,,0.6642985343933105,PMC11315474,PK - None | Study Population - Table 1
567,39380905,Population pharmacokinetic study in children with vascular anomalies: body weight as a key variable in predicting the initial dose and dosing frequency of sirolimus.,"Fan, Lin, Guo, Hong-Li, Zhao, Yue-Tao, Li, Yue, Wang, Wei-Jun, Huang, Jian, Hu, Ya-Hui, Zou, Ji-Jun, Chen, Feng",2024,"children, dosing recommendation, population pharmacokinetics, sirolimus, vascular anomalies",0.9636803269386292,PMC11458483,PK - TABLE 2 | Study Population - TABLE 1
